神戸市立医療センター中央市民病院　新型コロナウイルス感染症対策マニュアル

出版社： メディカ出版
著者：
発行日： 2021-10-20
分野： 臨床医学：内科  >  感染症/AIDS
ISBN： 9784840478199
電子書籍版： 2021-10-30 （電子書籍版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,960 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

「転んでも、ただでは起きない」 神戸市立医療センター中央市民病院が、職種を超え一丸となり、診療体制の再構築を図りながら作成した実践マニュアルを完全公開。Part 1でCOVID-19の基本的な知識を確認。Part 2で、院内感染対策から病院機能および診療体制の維持、チーム医療の実践から家族支援や職員のメンタルヘルスケアまで、医療者・非医療者問わず全職員が実践できる知識とノウハウを惜しみなく提供。自施設での対策に悩んだ際に“そのまま使える” 40のダウンロード資料つき（院内感染対策マニュアル、入院時チェックリスト、プロトコル、症状日誌、フロチャート、通知文、院内掲示ポスターなど）。

目次

  • 【Part1 新型コロナウイルス感染症の基本】
    ●Chapter1 COVID-19の疫学と変異株
    ●Chapter2 COVID-19と行政・法律
    ●Chapter3 COVID-19患者の臨床症状
    ●Chapter4 COVID-19の診断と検査
    ●Chapter5 術前・入院前のスクリーニング目的のSARS-CoV-2 PCR検査は必要か？
    ●Chapter6 COVID-19の治療
    ●Chapter7 COVID-19患者の隔離解除・退院基準
    ●Chapter8 COVID-19急性期からの回復後の症状持続と外来フォローアップ
    ●Chapter9 感染対策
    ●Chapter10 COVID-19ワクチン


    【Part2 新型コロナウイルス感染症対策の実際】
    ●Chapter1 COVID-19対策本部体制

    ●Chapter2 COVID-19院内感染対策
    ■1 新型コロナウイルス感染症感染対策マニュアル
    ■2 個人防護具着脱についての院内掲示ポスター
    ■3 院内注意喚起ポスター
    ■4 院内感染防止対策
    ■5 院内アウトブレイクへの対応

    ●Chapter3 COVID-19流行期の診療体制
    ■1 COVID-19病棟の診療体制
    ■2 COVID-19患者の外来・入院フロー
    ■3 保健所とのやり取りにおける工夫
    ■4 救急外来での対応・入院時チェックリスト
    ■5 予定入院時チェックリスト・症状日誌
    ■6 手術症例フローチャート
    ■7 スクリーニング目的の入院前PCR検査
    ■8 産科フローチャート

    ●Chapter4 COVID-19診療に関する院内マニュアル
    ■1 当直医・応援医師のための簡易マニュアル
    ■2 COVID-19患者に対するNPPVとCPAPの使用指針
    ■3 COVID-19患者に対するHFNCの使用指針
    ■4 非COVID-19患者に対するNPPV・HFNC・人工呼吸器（非閉鎖式回路）の使用指針
    ■5 重症COVID-19患者の呼吸管理
    ■6 COVID-19患者に対する気管挿管
    ■7 COVID-19患者における抜管
    ■8 COVID-19患者に対する経皮的気管切開
    ■9 COVID-19患者に対する腹臥位療法
    ■10 COVID-19患者におけるVV-ECMO適応基準
    ■11 ICUおよび一般病棟でのCOVID-19患者のCPA対応
    ■12 COVID-19病棟でのリハビリテーション
    ■13 COVID-19流行期の嚥下リハビリテーション
    ■14 COVID-19患者の往診
    ■15 COVID-19患者における呼吸困難の緩和

    ●Chapter5 チーム医療の実践
    ■1 病棟看護師が行うチーム医療の実践
    ■2 家族支援チームの活動
    ■3 多職種カンファレンス
    ■4 退院支援部門の関わり方

    ●Chapter6 家族の面会・病状説明
    ■1 Web面会
    ■2 FaceTime・LINEを使った面会
    ■3 COVID-19病棟での直接面会
    ■4 家族との面談と病状説明

    ●Chapter7 職員のメンタルヘルスケア
    ■1 精神・神経科の取り組み
    ■2 精神看護専門看護師（リエゾンナース）の取り組み
    ■3 外部からの支援

    ●Chapter8 外部からの支援
    ■1 他県からの看護師派遣受け入れ
    ■2 キッチンカーの出店

    ●Chapter9 神戸市立医療センター中央市民病院 COVID-19対応年表

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

Part 1 新型コロナウイルス感染症の基本

P.22 掲載の参考文献
1) 厚生労働省. 国内の発生状況など. https://www.mhlw.go.jp/stf/covid-19/kokunainohasseijoukyou.html [最終アクセス 2021.7.16]
 
2) 厚生労働省. 新型コロナウイルス感染症 (COVID-19) 診療の手引き 第5.1版. https://www.mhlw.go.jp/content/000801626.pdf [最終アクセス 2021.7.16]
 
3) 内閣官房. 新型コロナウイルス感染症対策. https://corona.go.jp/emergency/ [最終アクセス 2021.7.16]
 
4) 国立感染症研究所. まん延防止等重点措置と緊急事態宣言が新型コロナウイルス感染症の流行動態に及ぼした効果に関する定量的評価 (暫定版) (2021.6.14). https://www.niid.go.jp/niid/images/epi/corona/covid19-47.pdf [最終アクセス 2021.7.16]
 
5) 政府CIOポータル. 新型コロナワクチンの接種状況. https://cio.go.jp/c19vaccine_dashboard [最終アクセス 2021.7.16]
 
6) コロナ専門家有志の会. 2020年東京オリンピック・パラリンピック競技大会開催に伴う新型コロナウイルス感染拡大リスクに関する提言 (2021/6/18). https://note.stopcovid19.jp/n/n60ff3720a61a [最終アクセス 2021.7.16]
 
7) 厚生労働省. 第43回新型コロナウイルス感染症対策アドバイザリーボード (令和3年7月14日). 資料2-4 全国の新規陽性者数等及び高齢者のワクチン接種率等. https://www.mhlw.go.jp/content/10900000000806482.pdf [最終アクセス 2021.7.16]
 
8) 日本経済新聞. チャートで見る日本の感染状況 新型コロナウイルス. https://vdata.nikkei.com/newsgraphics/coronavirus-japan-chart/ [最終アクセス 2021.7.16]
 
9) 東洋経済ONLINE. 新型コロナウイルス 国内感染の状況. https://toyokeizai.net/sp/visual/tko/covid19/ [最終アクセス 2021.7.16]
 
10) World Health Organization. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ [最終アクセス 2021.7.16]
 
11) worldometer. https://www.worldometers.info/coronavirus/ [最終アクセス 2021.7.16]
 
12) Johns Hopkins University. Coronavirus resource center. https://coronavirus.jhu.edu/map.html [最終アクセス 2021.7.16]
 
13) 国立感染症研究所. 新型コロナウイルスSARS-CoV-2のゲノム分子疫学調査2. https://www.niid.go.jp/niid/ja/basic-science/467-genome/9787-genome-2020-2.html [最終アクセス 2021.7.16]
 
14) Wise J. Covid-19 : the E484K mutation and the risks it poses. BMJ. 2021 ; 372 : n359.
PubMed
15) 国立感染症研究所. 感染・伝播性の増加や抗原性の変化が懸念される新型コロナウイルス (SARS-CoV-2) の新規変異株について (第10報). https://www.niid.go.jp/niid/ja/diseases/ka/corona-virus/2019-ncov/2484-idsc/10501-covid19-48.html [最終アクセス 2021.7.16]
 
16) European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 8 July 2021. https://www.ecdc.europa.eu/en/covid-19/variants-concern [最終アクセス 2021.7.16]
 
17) Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html [最終アクセス 2021.7.16]
 
18) World Health Organization. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ [最終アクセス 2021.7.16]
 
19) Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants - clinical, public health, and vaccine implications. N Engl J Med. 2021 ; 384 : 1866-8.
PubMed
20) Ito K, et al. Predicted dominance of variant Delta of SARS-CoV-2 before Tokyo Olympic Games, Japan, July 2021. Euro Surveill. 2021 ; 26 (27) : 2100570.
PubMed
21) Davies NG, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021 ; 372 (6538) : eabg3055.
PubMed
22) Nyberg T, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7 : cohort analysis. BMJ. 2021 ; 373 : n1412.
PubMed
23) Funk T, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1 : data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill. 2021 ; 26 ( 16) : 2100348.
PubMed
24) Frampton D, et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK : a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis. 2021 ; S1473-3099 (21) 00170-5.
 
25) Challen R, et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1 : matched cohort study. BMJ. 2021 ; 372 : n579.
PubMed
26) Davies NG, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021 ; 593 : 270-4.
PubMed
27) Grint DJ, et al. Case fatality risk of the SARSCoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February. Euro Surveill. 2021 ; 26 (11) : 2100256.
 
28) Madhi SA, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 ; 384 : 1885-98.
 
29) Abu-Raddad LJ, et al. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021 ; 385 : 187-9.
 
30) Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England, Technical briefing 15 (11 June 2021). https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/993879/Variants_of_Concern_VOC_Technical_Briefing_15.pdf [最終アクセス 2021.7.16]
 
31) Sheikh A, et al. SARS-CoV-2 Delta VOC in Scotland : demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021 ; 397 : 2461-2.
PubMed
32) Wall EC, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021 ; 397 : 2331-3.
 
33) Bernal JL, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv 2021.05.22.21257658 ; doi : https://doi.org/10.1101/2021.05.22.21257658 [最終アクセス 2021.7.16]
 
34) Petersen E, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020 ; 20 : e238-e44.
PubMed
35) Stringhini S, et al. Seroprevalence of anti-SARSCoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP) : a population-based study. Lancet. 2020 ; 396 : 313-9.
 
36) Russell TW, et al. Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Euro Surveill. 2020 ; 25 (12) : 2000256.
PubMed
37) Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 ; 323 : 1239-42.
 
38) Perez-Saez J, et al. Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland. Lancet Infect Dis. 2021 ; 21 : e69-e70.
PubMed
39) Faust JS, Del Rio C. Assessment of deaths from COVID-19 and from seasonal influenza. JAMA Intern Med. 2020 ; 180 : 1045-6.
PubMed
40) Centers for Disease Control and Prevention. Disease Burden of Influenza. https://www.cdc.gov/flu/about/burden/index.html [最終アクセス 2021.7.16]
 
41) Faust JS, et al. Comparison of estimated excess deaths in New York city during the COVID-19 and 1918 influenza pandemics. JAMA Netw Open. 2020 ; 3 : e2017527.
PubMed
42) Chertow DS, Memoli MJ. Bacterial coinfection in influenza : a grand rounds review. JAMA. 2013 ; 309 : 275-82.
PubMed
43) Metersky ML, et al. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012 ; 16 : e321-31.
PubMed
44) Kaiser L, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003 ; 163 : 1667-72.
PubMed
45) Hayashi Y, et al. Influenza-associated bacterial pathogens in patients with 2009 influenza A (H1N1) infection : impact of community-associated methicillin-resistant Staphylococcus aureus in Queensland, Australia. Intern Med J. 2012 ; 42 : 755-60.
PubMed
46) Xie Y, et al. Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza : cohort study. BMJ. 2020 ; 371 : m4677.
PubMed
47) Piroth L, et al. Comparison of the characteristics, morbidit y, and mor tality of COV ID-19 and seasonal influenza : a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021 ; 9 : 251-9.
 
48) Talbot HK, et al. Coronavirus disease 2019 (COVID-19) versus influenza in hospitalized adult patients in the United States : differences in demographic and severity indicators. Clin Infect Dis. 2021 ; ciab123.
PubMed
P.25 掲載の参考文献
1) 厚生労働省. 新型コロナウイルス感染症の感染症法の運用の見直しについて (2020/9/25). https://www.mhlw.go.jp/content/10906000/000675463.pdf [最終アクセス 2021.7.13]
 
2) 厚生労働省. 「感染症の予防及び感染症の患者に対する医療に関する法律等の改正について」に関するQ&A (2021/2/10). https://www.mhlw.go.jp/content/000737653.pdf [最終アクセス 2021.7.13]
 
3) 厚生労働省. 新型コロナウイルス感染症に関する現状と取組について (2020/10/28). https://www.mhlw.go.jp/content/10906000/000688556.pdf [最終アクセス 2021.7.13]
 
P.30 掲載の参考文献
1) Li Q, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 ; 382 : 1199-207.
PubMed
2) Guan W, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 ; 382 : 1708-20.
 
3) Chan JF, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission : a study of a family cluster. Lancet. 2020 ; 395 : 514-23.
PubMed
4) Lauer SA, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases : estimation and application. Ann Intern Med. 2020 ; 172 : 577-82.
PubMed
5) Cohen PA, et al. The early natural history of SARS-CoV-2 infection : clinical observations from an Urban, Ambulatory COVID-19 Clinic. Mayo Clin Proc. 2020 ; 95 : 1124-6.
 
6) Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study. Lancet. 2020 ; 395 : 1054-62.
 
7) Wang D, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China. JAMA. 2020 ; 323 : 1061-9.
PubMed
8) Yang X, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China : a single-centered, retrospective, observational study. Lancet Respir Med. 2020 ; 8 : 475-81.
 
9) Berlin DA, et al. Severe Covid-19. N Engl J Med. 2020 ; 383 : 2451-60.
PubMed
10) 厚生労働省. 新型コロナウイルス感染症 (COVID-19) 診療の手引き 第5.1版. https://www.mhlw.go.jp/content/000801626.pdf [最終アクセス 2021.7.9]
 
11) McGrath BA, et al. Tracheostomy in the COVID-19 era : global and multidisciplinary guidance. Lancet Respir Med. 2020 ; 8 : 717-25.
PubMed
12) Docherty AB, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol : prospective observational cohort study. BMJ. 2020 ; 369 : m1985.
PubMed
13) Stokes EK, et al. Coronavirus disease 2019 case surveillance-United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020 ; 69 : 759-65.
PubMed
14) Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus Disease 2019 (COVID-19) outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 ; 323 : 1239-42.
 
15) Wiersinga WJ, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19) : a review. JAMA. 2020 ; 324 : 782-93.
PubMed
16) Dhont S, et al. The pathophysiology of 'happy' hypoxemia in COVID-19. Respir Res. 2020 ; 21 : 198.
 
17) Couzin-Frankel J. The mystery of the pandemic's 'happy hypoxia'. Science. 2020 ; 368 : 455-6.
PubMed
18) Simonson TS, et al. Silent hypoxaemia in COVID-19 patients. J Physiol. 2021 ; 599 : 1057-65.
PubMed
19) Tobin MJ, et al. Why COVID-19 silent hypoxemia is baffling to physicians. Am J Respir Crit Care Med. 2020 ; 202 : 356-60.
PubMed
20) Brouqui P, et al. Asymptomatic hypoxia in COVID-19 is associated with poor outcome. Int J Infect Dis. 2021 ; 102 : 233-8.
PubMed
21) Chatterjee NA, et al. Admission respiratory status predicts mortality in COVID-19. Influenza Other Respir Viruses. 2021 ; 10.1111/irv.12869.
 
22) Tong JY, et al. The prevalence of olfactory and gustatory dysfunction in COVID-19 patients : a systematic review and meta-analysis. Otolaryngol Head Neck Surg. 2020 ; 163 : 3-11.
PubMed
23) Lovato A, et al. Comment on "The Prevalence of Olfactory and Gustatory Dysfunction in COVID-19 Patients : A Systematic Review and Meta-analysis". Otolaryngol Head Neck Surg. 2020 ; 163 : 852.
PubMed
24) Lechien JR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-tomoderate forms of the coronavirus disease (COVID-19) : a multicenter European study. Eur Arch Otorhinolaryngol. 2020 ; 277 : 2251-61.
 
25) Spinato G, et al. Alterations in smell or taste in mildly symptomatic outpatients with SARS-CoV-2 infection. JAMA. 2020 ; 323 : 2089-90.
 
26) Kaye R, et al. COVID-19 anosmia reporting tool : initial findings. Otolaryngol Head Neck Surg. 2020 ; 163 : 132-4.
PubMed
27) Wee LE, et al. The role of self-reported olfactory and gustatory dysfunction as a screening criterion for suspected COVID-19. Eur Arch Otorhinolaryngol. 2020 ; 277 : 2389-90.
PubMed
28) Agyeman AA, et al. Smell and taste dysfunction in patients with COVID-19 : a systematic review and meta-analysis. Mayo Clin Proc. 2020 ; 95 : 1621-31.
PubMed
29) Mao L, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020 ; 77 : 683-90.
PubMed
30) Giacomelli A, et al. Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection : a crosssectional study. Clin Infect Dis. 2020 ; 71 : 889-90.
PubMed
31) Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19 : diagnosis and management. JAMA. 2020 ; 323 : 2512-4.
PubMed
32) Foster KJ, et al. Smell loss is a prognostic factor for lower severity of coronavirus disease 2019. Ann Allergy Asthma Immunol. 2020 ; 125 : 481-3.
PubMed
33) National Institutes of Health. COVID-19 Treatment Guidelines. Clinical Spectrum of SARS-CoV-2 Infection. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ [最終アクセス 2021.7.9]
 
34) WHO. COVID-19 Clinical management : living guidance. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 [最終アクセス 2021.7.9]
 
35) Rawson TM, et al. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect. 2021 ; 27 : 9-11.
PubMed
36) Garcia-Vidal C, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19 : a retrospective cohort study. Clin Microbiol Infect. 2021 ; 27 : 83-8.
PubMed
37) Kolenda C, et al. Assessment of respiratory bacterial coinfections among severe acute respiratory syndrome coronavirus 2-positive patients hospitalized in intensive care units using conventional culture and BioFire, FilmArray Pneumonia Panel Plus Assay. Open Forum Infect Dis. 2020 ; 7 : ofaa484.
PubMed
38) Lehmann CJ, et al. Community-acquired coinfection in coronavirus Disease 2019 : a retrospective observational experience. Clin Infect Dis. 2021 ; 72 : 1450-2.
PubMed
39) Lansbury L, et al. Co-infections in people with COVID-19 : a systematic review and meta-analysis. J Infect. 2020 ; 81 : 266-75.
PubMed
40) Langford BJ, et al. Bacterial co-infection and secondary infection in patients with COVID-19 : a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 ; 26 : 1622-9.
PubMed
41) Sepulveda J, et al. Bacteremia and blood culture utilization during COVID-19 surge in New York City. J Clin Microbiol. 2020 ; 58 (8) : e00875-20.
PubMed
42) Kim D, et al. Rates of co-infection between SARSCoV-2 and other respiratory pathogens. JAMA. 2020 ; 323 : 2085-6.
 
43) Richardson S, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 ; 323 : 2052-9.
PubMed
44) Rawson TM, et al. Bacterial and fungal coinfection in individuals with coronavirus : a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020 ; 71 : 2459-68.
PubMed
45) White PL, et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis. 2020 ; ciaa1298.
 
46) Vaughn VM, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus Disease 2019 (COVID-19) : a multi-hospital cohort study. Clin Infect Dis. 2021 ; 72 : e533-e41.
PubMed
47) Garcia-Vidal C, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19 : a retrospective cohort study. Clin Microbiol Infect. 2021 ; 27 : 83-8.
PubMed
48) Ripa M, et al. Secondary infections in patients hospitalized with COVID-19 : incidence and predictive factors. Clin Microbiol Infect. 2021 ; 27 : 451-7.
PubMed
49) Hoenigl M. Invasive fungal disease complicating COVID-19 : when it rains it pours. Clin Infect Dis. 2020 ; ciaa1342.
 
50) Koehler P, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020 ; 63 : 528-34.
PubMed
51) Blaize M, et al. Fatal invasive aspergillosis and coronavirus disease in an immunocompetent patient. Emerg Infect Dis. 2020 ; 26 : 1636-7.
 
52) van Arkel ALE, et al. COVID-19-associated pulmonary Aspergillosis. Am J Respir Crit Care Med. 2020 ; 202 : 132-5.
PubMed
53) Alanio A, et al. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020 ; 8 : e48-e9.
PubMed
54) Delliere S, et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients : a French multicentric retrospective cohort. Clin Microbiol Infect. 2020 ; 27 : 790e1-5.
PubMed
55) Fekkar A, et al. Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU. Am J Respir Crit Care Med. 2021 ; 203 : 307-17.
 
P.40 掲載の参考文献
1) Wu C, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 ; 180 : 934-43.
PubMed
2) Ma t sumoto K, et al. Does asthma affect morbidity or severity of COVID-19? J Allergy Clin Immunol. 2020 ; 146 : 55-7.
 
3) Zadori N, et al. The negative impact of comorbidities on the disease course of COVID-19. Intensive Care Med. 2020 ; 46 : 1784-6.
PubMed
4) Pujadas E, et al. SARS-CoV-2 viral load predicts COVID-19 mortality. Lancet Respir Med. 2020 ; 8 : e70.
PubMed
5) Du Y, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study. Am J Respir Crit Care Med. 2020 ; 201 : 1372-9.
PubMed
6) Zhou F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China : a retrospective cohort study. Lancet. 2020 ; 395 : 1054-62.
 
7) Chen R, et al. Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China. Chest. 2020 ; 158 : 97-105.
 
8) Haberman R, et al. Covid-19 in immune-mediated inflammatory diseases - case series from New York. N Engl J Med. 2020 ; 383 : 85-8.
PubMed
9) Wang K, et al. Clinical and laboratory predictors of in-hospital mortality in patients with coronavirus disease-2019 : a cohort study in Wuhan, China. Clin Infect Dis. 2020 ; 71 : 2079-88.
PubMed
10) Zhang L, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020 ; 18 : 1324-9.
 
11) Wang L, et al. Coronavirus disease 2019 in elderly patients : characteristics and prognostic factors based on 4-week follow-up. J Infect. 2020 ; 80 : 639-45.
PubMed
12) Du RH, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARSCoV-2 : a prospective cohort study. Eur Respir J. 2020 ; 55.
 
13) Petrilli CM, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City : prospective cohort study. BMJ. 2020 ; 369 : m1966.
PubMed
14) Williamson EJ, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 ; 584 : 430-6.
PubMed
15) Tartof SY, et al. Obesity and mortality among patients diagnosed with COVID-19 : results from an integrated health care organization. Ann Intern Med. 2020 ; 173 : 773-81.
PubMed
16) Shi S, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020 ; 5 : 802-10.
PubMed
17) Liang W, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020 ; 180 : 1081-9.
PubMed
18) Latif F, et al. Characteristics and outcomes of recipients of heart transplant with coronavirus disease 2019. JAMA Cardiol. 2020 ; 5 : 1165-9.
PubMed
19) Hewitt J, et al. The effect of frailty on survival in patients with COVID-19 (COPE) : a multicentre, European, observational cohort study. Lancet Public Health. 2020 ; 5 : e444-e51.
 
20) Kates OS, et al. COV ID -19 in solid organ transplant : a multi-center cohort study. Clin Infect Dis. 2020.
 
21) Popkin BM, et al. Individuals with obesity and COVID-19 : a global perspective on the epidemiology and biological relationships. Obes Rev. 2020 ; 21 : e13128.
 
22) Cunningham JW, et al. Clinical outcomes in young US adults hospitalized with COVID-19. JAMA Intern Med. 2020 ; 181 : 379-81.
PubMed
23) Knight SR, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol : development and validation of the 4C Mortality Score. BMJ. 2020 ; 370 : m3339.
PubMed
24) Geretti AM, et al. Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK) : a prospective observational study. Clin Infect Dis. 2020.
 
25) Bryan A, et al. SARS-CoV-2 viral load on admission is associated with 30-day mortality. Open Forum Infect Dis. 2020 ; 7 : ofaa535.
PubMed
26) Westblade LF, et al. SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell. 2020 ; 38 : 661-71e2.
PubMed
27) Rao SN, et al. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. Infect Dis Ther. 2020 ; 9 : 573-86.
PubMed
28) Zambrano LD, et al. Update : characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status-United States, January 22-October 3, 2020. MMWR Morb Mortal Wkly Rep. 2020 ; 69 : 1641-7.
PubMed
29) Martinez-Portilla RJ, et al. Pregnant women with SARS-CoV-2 infection are at higher risk of death and pneumonia : propensity score matched analysis of a nationwide prospective cohort (COV19Mx). Ultrasound Obstet Gynecol. 2021 ; 57 : 224-31.
PubMed
30) Allotey J, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy : living systematic review and meta-analysis. BMJ. 2020 ; 370 : m3320.
PubMed
31) Gao M, et al. Associations between body-mass index and COVID-19 severity in 6・9 million people in England : a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021 ; 9 : 350-9.
 
32) Centers for Disease Control and Prevention. Risk for COVID-19 Infection, Hospitalization, and Death By Age Group. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-deathby-age.html [最終アクセス 2021.7.21]
 
33) Ko JY, et al. Risk factors for coronavirus disease 2019 (COVID-19) -associated hospitalization : COVID-19-associated hospitalization surveillance network and behavioral risk factor surveillance system. Clin Infect Dis. 2021 ; 72 : e695-e703.
PubMed
34) Mustafa Hellou M, et al. Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections : a systematic review and meta-analysis. Clin Microbiol Infect. 2021 ; 27 : 341-51.
PubMed
35) Kucirka LM, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020 ; 173 : 262-7.
PubMed
36) 厚生労働省. 新型コロナウイルス感染症 (COVID-19) 病原体検査の指針 第4版. https://www.mhlw.go.jp/content/000788513.pdf [最終アクセス 2021.7.21]
 
37) Inaba M, et al. Diagnostic accuracy of LAMP versus PCR over the course of SARS-CoV-2 infection. Int J Infect Dis. 2021 ; 107 : 195-200.
PubMed
38) Wang W, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020 ; 323 : 1843-4.
PubMed
39) Yu F, et al. Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients. Clin Infect Dis. 2020 ; 71 : 793-8.
PubMed
40) Zou L, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020 ; 382 : 1177-9.
PubMed
41) Pasomsub E, et al. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019 : a cross-sectional study. Clin Microbiol Infect. 2021 ; 27 : 285 e1-e4.
 
42) Williams E, et al. Saliva as a noninvasive specimen for detection of SARS-CoV-2. J Clin Microbiol. 2020 ; 58.
PubMed
43) Azzi L, et al. Saliva is a reliable tool to detect SARS-CoV-2. J Infect. 2020 ; 81 : e45-e50.
PubMed
44) Fang Z, et al. Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients. J Infect. 2020 ; 81 : 147-78.
PubMed
45) Iwasaki S, et al. Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. J Infect. 2020 ; 81 : e145-e7.
 
46) Nagura-Ikeda M, et al. Clinical evaluation of self-collected saliva by quantitative reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription-loop-mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19. J Clin Microbiol. 2020 ; 58.
 
47) Yokota I, et al. Mass screening of asymptomatic persons for SARS-CoV-2 using saliva. Clin Infect Dis. 2020.
 
48) Nomoto H, et al. Cautious handling of urine from moderate to severe COVID-19 patients. Am J Infect Control. 2020 ; 48 : 969-71.
PubMed
49) Xiao F, et al. Infectious SARS-CoV-2 in feces of patient with severe COVID-19. Emerg Infect Dis. 2020 ; 26 : 1920-2.
PubMed
50) Okuhama A, et al. Detection of SARS-CoV-2 in hemodialysis effluent of patient with COVID-19 pneumonia, Japan. Emerg Infect Dis. 2020 ; 26 : 2758-61.
PubMed
51) Li D, et al. Clinical characteristics and results of semen tests among men with coronavirus disease 2019. JAMA Netw Open. 2020 ; 3 : e208292.
PubMed
52) Kang M, et al. Probable evidence of fecal aerosol transmission of SARS-CoV-2 in a high-rise building. Ann Intern Med. 2020 ; 173 : 974-80.
 
53) Mei F, et al. First detection of SARS-CoV-2 by real-time reverse transcriptase-polymerase chain reaction assay in pleural fluid. Chest. 2020 ; 158 : e143-e6.
PubMed
54) Cheung KS, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort : systematic review and meta-analysis. Gastroenterology. 2020 ; 159 : 81-95.
PubMed
55) Colavita F, et al. SARS-CoV-2 isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection. Ann Intern Med. 2020 ; 173 : 242-3.
PubMed
56) Zheng S, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020 : retrospective cohort study. BMJ. 2020 ; 369 : m1443.
PubMed
57) Tu YP, et al. Swabs collected by patients or health care workers for SARS-CoV-2 testing. N Engl J Med. 2020 ; 383 : 494-6.
 
58) Wehrhahn MC, et al. Self-collection : an appropriate alternative during the SARS-CoV-2 pandemic. J Clin Virol. 2020 ; 128 : 104417.
PubMed
59) Pere H, et al. Nasal swab sampling for SARSCoV-2 : a convenient alternative in times of nasopharyngeal swab shortage. J Clin Microbiol. 2020 ; 58.
 
60) Wu J, et al. Clinical characteristics of imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu Province : a multicenter descriptive study. Clin Infect Dis. 2020 ; 71 : 706-12.
 
61) Fang Y, et al. Sensitivity of chest CT for COVID-19 : comparison to RT-PCR. Radiology. 2020 ; 296 : E115-E7.
PubMed
62) Lee TH, et al. Testing for SARS-CoV-2 : Can we stop at 2? Clin Infect Dis. 2020 ; 71 : 2246-8.
PubMed
63) Richardson S, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 ; 323 : 2052-9.
PubMed
64) Kennedy AJ, et al. Retesting for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) : patterns of testing from a large US healthcare system. Infect Control Hosp Epidemiol. 2020 : 1-3.
 
65) Long DR, et al. Occurrence and timing of subsequent severe acute respiratory syndrome coronavirus 2 reverse-transcription polymerase chain reaction positivity among initially negative patients. Clin Infect Dis. 2021 ; 72 : 323-6.
PubMed
66) Hanson KE, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19 : Molecular Diagnostic Testing. Infectious Diseases Society of America 2020 ; Version 2.0.0. https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics/ [最終アクセス 2021.7.21]
 
67) 厚生労働省. 新型コロナウイルス感染症の体外診断用医薬品 (検査キット) の承認情報. https://www.mhlw.go.jp/stf/newpage_11331.html [最終アクセス 2021.7.21]
 
68) Hanson KE, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19 : Antigen Testing. Infectious Diseases Society of America 2021 ; Version 1.0.0. https://www.idsociety.org/practice-guideline/covid-19-guideline-antigen testing/ [最終アクセス 2021.7.21]
 
69) Guo L, et al. Profiling early humoral response to diagnose novel coronavirus disease ( COVID-19). Clin Infect Dis. 2020 ; 71 : 778-85.
PubMed
70) To KK, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2 : an observational cohort study. Lancet Infect Dis. 2020 ; 20 : 565-74.
PubMed
71) Zhao J, et al. Antibody responses to SARSCoV-2 in patients with novel coronavirus disease 2019. Clin Infect Dis. 2020 ; 71 : 2027-34.
 
72) Liu W, et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J Clin Microbiol. 2020 ; 58.
PubMed
73) Pan Y, et al. Serological immunochromatographic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infect. 2020 ; 81 : e28-e32.
PubMed
74) Padoan A, et al. Analytical performances of a chemiluminescence immunoassay for SARSCoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med. 2020 ; 58 : 1081-8.
 
75) Lippi G, et al. Assessment of immune response to SARS-CoV-2 with fully automated MAGLUMI 2019-nCoV IgG and IgM chemiluminescence immunoassays. Clin Chem Lab Med. 2020 ; 58 : 1156-9.
PubMed
76) Xiang F, et al. Antibody detection and dynamic characteristics in patients with coronavirus disease 2019. Clin Infect Dis. 2020 ; 71 : 1930-4.
PubMed
77) Long QX, et al. Antibody responses to SARSCoV-2 in patients with COVID-19. Nat Med. 2020 ; 26 : 845-8.
 
78) Amanat F, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020 ; 26 : 1033-6.
PubMed
79) Kirkcaldy RD, et al. COVID-19 and postinfection immunity : limited evidence, many remaining questions. JAMA. 2020 ; 323 : 2245-6.
PubMed
80) Bryan A, et al. Performance characteristics of the Abbott Architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol. 2020 ; 58.
PubMed
81) Nakano Y, et al. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan. Sci Rep. 2021 ; 11 : 2776.
PubMed
82) Hanson KE, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19 : Serologic Testing. Infectious Diseases Society of America 2020 ; Version 1.0.0. https://www.idsociety.org/practice-guideline/covid-19-guideline-serology/ [最終アクセス 2021.7.21]
 
83) Long QX, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 ; 26 : 1200-4.
PubMed
84) Stephens DS, et al. COVID-19 and the Path to Immunity. JAMA. 2020 ; 324 : 1279-81.
PubMed
85) 国立感染症研究所. インフルエンザ流行レベルマップ. https://nesid4g.mhlw.go.jp/Hasseidoko/Levelmap/flu/new_jmap.html [最終アクセス 2021.7.21]
 
86) Kim D, et al. Rates of co-infection between SARS-CoV-2 and other respiratory pathogens. JAMA. 2020 ; 323 : 2085-6.
PubMed
87) Cuadrado-Payan E, et al. SARS-CoV-2 and influenza virus co-infection. Lancet. 2020 ; 395 : e84.
PubMed
88) Ding Q, et al. The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol. 2020 ; 92 : 1549-55.
 
89) Ma S, et al. Clinical characteristics of critically ill patients co-infected with SARS-CoV-2 and the influenza virus in Wuhan, China. Int J Infect Dis. 2020 ; 96 : 683-7.
PubMed
90) Yue H, et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. J Med Virol. 2020 ; 92 : 2870-3.
PubMed
91) Lehmann CJ, et al. Community-acquired coinfection in coronavirus disease 2019 : a retrospective observational experience. Clin Infect Dis. 2021 ; 72 : 1450-2.
PubMed
92) Iacobucci G. Covid-19 : Risk of death more than doubled in people who also had flu, English data show. BMJ. 2020 ; 370 : m3720.
PubMed
93) Uyeki TM, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America : 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 ; 68 : e1-e47.
 
94) 一般社団法人日本感染症学会. インフルエンザ-COVID-19アドホック委員会. 一般社団法人日本感染症学会提言 今冬のインフルエンザとCOVID-19に備えて (2020/8/3). https://www.kansensho.or.jp/modules/guidelines/index.php?content_id=41 [最終アクセス 2021.7.21]
 
95) Wong HYF, et al. Frequency and distribution of chest radiographic findings in patients positive for COVID-19. Radiology. 2020 ; 296 : E72-E8.
PubMed
96) Guan WJ, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 ; 382 : 1708-20.
 
97) Matsunaga N, et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan : Report of the COVID-19 REGISTRY JAPAN. Clin Infect Dis. 2020 ; ciaa1470.
 
98) Miro O, et al. Frequency, risk factors, clinical characteristics, and outcomes of spontaneous pneumothorax in patients with coronavirus disease 2019 : a case-control, emergency medicine-based multicenter study. Chest. 2021 ; 159 : 1241-55.
PubMed
99) Shi H, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China : a descriptive study. Lancet Infect Dis. 2020 ; 20 : 425-34.
 
100) Pan F, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology. 2020 ; 295 : 715-21.
PubMed
101) Xiong Y, et al. Clinical and high-resolution CT features of the COVID-19 infection : comparison of the initial and follow-up changes. Invest Radiol. 2020 ; 55 : 332-9.
PubMed
102) 診療の手引検討委員会. 新型コロナウイルス感染症 (COVID-19) 診療の手引き 第5版. https://www.mhlw.go.jp/content/000785119.pdf [最終アクセス 2021.7.21]
 
103) Lansbury L, et al. Co-infections in people with COVID-19 : a systematic review and meta-analysis. J Infect. 2020 ; 81 : 266-75.
PubMed
104) Langford BJ, et al. Bacterial co-infection and secondary infection in patients with COVID-19 : a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 ; 26 : 1622-9.
PubMed
105) Vaughn VM, et al. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19) : a multi-hospital cohort study. Clin Infect Dis. 2021 ; 72 : e533-e41.
PubMed
106) Garcia-Vidal C, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19 : a retrospective cohort study. Clin Microbiol Infect. 2021 ; 27 : 83-8.
PubMed
107) Kolenda C, et al. Assessment of respiratory bacterial coinfections among severe acute respiratory syndrome coronavirus 2-positive patients hospitalized in intensive care units using conventional culture and BioFire, FilmArray Pneumonia Panel Plus Assay. Open Forum Infect Dis. 2020 ; 7 : ofaa484.
PubMed
108) Rawson TM, et al. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect. 2021 ; 27 : 9-11.
PubMed
109) Sieswerda E, et al. Recommendations for antibacterial therapy in adults with COVID-19-an evidence based guideline. Clin Microbiol Infect. 2021 ; 27 : 61-6.
PubMed
110) De Waele JJ, et al. Antimicrobial stewardship in ICUs during the COVID-19 pandemic : back to the 90s? Intensive Care Med. 2021 ; 47 : 104-6.
 
P.47 掲載の参考文献
1) Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 ; 323 : 1239-42.
 
2) Mizumoto K, et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020 ; 25 (10) : 2000180.
PubMed
3) Tabata S, et al. Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship : a retrospective analysis. Lancet Infect Dis. 2020 ; 20 : 1043-50.
 
4) Hoxha A, et al. Asymptomatic SARS-CoV-2 infection in Belgian long-term care facilities. Lancet Infect Dis. 2021 ; 21 : e67.
PubMed
5) Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection : a narrative review. Ann Intern Med. 2020 ; 173 : 362-7.
PubMed
6) Oran DP, Topol EJ. The proportion of SARS-CoV-2 infections that are asymptomatic : a systematic review. Ann Intern Med. 2021 ; 174 : 655-62.
PubMed
7) Furuse Y, et al. Clusters of coronavirus disease in communities, Japan, January-April 2020. Emerg Infect Dis. 2020 ; 26 : 2176-9.
PubMed
8) Plucinski MM, et al. Coronavirus disease 2019 (COVID-19) in Americans aboard the Diamond Princess cruise ship. Clin Infect Dis. 2021 ; 72 : e448-e57.
PubMed
9) Ferretti L, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science. 2020 ; 368 (6491) : eabb6936.
PubMed
10) Hu Z, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020 ; 63 : 706-11.
PubMed
11) Bai Y, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020 ; 323 : 1406-7.
PubMed
12) Wang Y, et al. Characterization of an asymptomatic cohort of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected individuals outside of Wuhan, China. Clin Infect Dis. 2020 ; 71 : 2132-8.
PubMed
13) Lee S, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. JAMA Intern Med. 2020 ; 180 : 1447-52.
 
14) Arons MM, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020 ; 382 : 2081-90.
 
15) Hanson KE, et al. Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19 : Molecular Diagnostic Testing. Infectious Diseases Society of America 2020 ; Version 2.0.0. https://www.idsociety.org/practice-guideline/covid-19-guideline-diagnostics/ [最終アクセス 2001.7.10]
 
16) Lei S, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. E Clinical Medicine. 2020 ; 21 : 100331.
 
17) COVID Surg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection : an international cohort study. Lancet. 2020 ; 396 : 27-38.
PubMed
18) Surkova E, et al. False-positive COVID-19 results : hidden problems and costs. Lancet Respir Med. 2020 ; 8 : 1167-8.
PubMed
19) Skit trall JP, et al. Specificity and positive predictive value of SARS-CoV-2 nucleic acid amplification testing in a low-prevalence setting. Clin Microbiol Infect. 2021 ; 27 : 469 e9-e15.
 
20) Uchida S, et al. CT screening for COVID-19 in asymptomatic patients before hospital admission. J Infect Chemother. 2021 ; 27 : 232-6.
PubMed
P.57 掲載の参考文献
1) Demoule A, et al. High-flow nasal cannula in critically III patients with severe COVID-19. Am J Respir Crit Care Med. 2020 ; 202 : 1039-42.
PubMed
2) Guy T, et al. High-flow nasal oxygen : a safe, efficient treatment for COVID-19 patients not in an ICU. Eur Respir J. 2020 ; 56 (5) : 2001154.
PubMed
3) Li J, et al. High-flow nasal cannula for COVID-19 patients : low risk of bio-aerosol dispersion. Eur Respir J. 2020 ; 55 (5) : 2000892.
PubMed
4) Franco C, et al. Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia. Eur Respir J. 2020 ; 56 (5) : 2002130.
PubMed
5) Frat JP, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015 ; 372 : 2185-96.
PubMed
6) Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states : a clinicaltherapeutic staging proposal. J Heart Lung Transplant. 2020 ; 39 : 405-7.
 
7) Sundararaj Stanleyraj J, et al. Treating COVID-19 : are we missing out the window of opportunity? J Antimicrob Chemother. 2021 ; 76 : 283-5.
PubMed
8) Cevik M, et al. Virology, transmission, and pat hogenesis of SARS-CoV-2. BMJ. 2020 ; 371 : m3862.
 
9) Dougan M, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N Engl J Med. 2021. doi : 10.1056/NEJMoa2102685.
 
10) National Institutes of Health. COVID-19 Treatment Guidelines. Anti-SARS-CoV-2 Monoclonal Antibodies. (2021/5/24) https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/ [最終アクセス 2021.7.18]
 
11) Weinreich DM, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 2021 ; 384 : 238-51.
PubMed
12) Weinreich DM, et al. REGEN-COV antibody cocktail clinical outcomes study in covid-19 outpatients. medRxiv 2021.05.19.21257469 ; doi : https://doi.org/10.1101/2021.05.19.21257469 [最終アクセス 2021.7.18]
 
13) National Institutes of Health. COVID-19 Treatment Guidelines. Therapeutic Management of Nonhospitalized Adults With COVID-19. (2021/7/8) https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalizedadults--therapeutic-management/ [最終アクセス 2021.7.18]
 
14) National Institutes of Health. COVID-19 Treatment Guidelines. The COVID-19 Treatment Guidelines Panel's Statement on the Emergency Use Authorizations of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19. (2021/7/8) https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-anti-sars-cov-2-monoclonal-antibodies-eua/ [最終アクセス 2021.7.18]
 
15) Doi Y, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020 ; 64 (12) : e01897-20.
PubMed
16) Ivashchenko AA, et al. AVIFAVIR for treatment of patients with moderate COVID-19 : interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2020 ; ciaa1176.
PubMed
17) Hassanipour S, et al. The efficacy and safety of Favipiravir in treatment of COVID-19 : a systematic review and meta-analysis of clinical trials. Sci Rep. 2021 ; 11 : 11022.
PubMed
18) Hase R, et al. Acute gouty ar thritis during favipiravir treatment for coronavirus disease 2019. Intern Med. 2020 ; 59 : 2327-9.
 
19) Irie K, et al. Pharmacokinetics of favipiravir in critically ill patients with COVID-19. Clin Transl Sci. 2020 ; 13 : 880-5.
PubMed
20) Pramesh CS, et al. Choosing wisely for COVID-19 : ten evidence-based recommendations for patients and physicians. Nat Med. 2021. doi : 10.1038/s41591-021-01439-x.
 
21) Roman YM, et al. Ivermectin for the treatment of COVID-19 : a systematic review and meta-analysis of randomized controlled trials. Clin Infect Dis. 2021 ; ciab591.
PubMed
22) Vallejos J, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. BMC Infect Dis. 2021 ; 21 : 635.
PubMed
23) Podder C, et al. Outcome of ivermectin treated mild to moderate COVID-19 cases : a singlecentre, open-label, randomised controlled study. IMC Journal of Medical Science, 2021 ; 14 (2) : 11-18. https://doi.org/10.3329/imcjms.v14i2.52826
 
24) Aijaz Zeeshan Khan Chachar, et al. Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients. International Journal of Sciences 2020 ; 9 : 31-35. DOI : 10.18483/ijSci.2378
 
25) Ahmed S, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. Int J Infect Dis. 2021 ; 103 : 214-6.
 
26) Chaccour C, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19 : a pilot, double-blind, placebo-controlled, randomized clinical trial. E Clinical Medicine. 2021 ; 32 : 100720.
 
27) Lopez-Medina E, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19 : a randomized clinical trial. JAMA. 2021 ; 325 : 1426-35.
PubMed
28) Bryant A, et al. Ivermectin for prevention and treatment of COVID-19 infection : a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021 ; 28 : e434-e60.
 
29) Hill A, et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Open Forum Infectious Diseases, 2021 ;, ofab358. https://doi.org/10.1093/ofid/ofab358
 
30) Elgazzar A, et al. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. Research Square. doi : 10.21203/rs.3.rs-100956/v3. https://www.researchsquare.com/article/rs-100956/v3
 
31) Jean-Claude Tardif, et al. Efficacy of colchicine in non-hospitalized patients with COVID-19. medRxiv 2021. 01. 26. 21250494 ; doi : https://doi.org/10.1101/2021.01.26.21250494
 
32) Deftereos SG, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019 : The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 2020 ; 3 : e2013136.
PubMed
33) RECOVERY Collaborative Group. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial. medRxiv 2021. 05. 18. 21257267 ; doi : https://doi.org/10.1101/2021.05.18.21257267
 
34) Ramakrishnan S, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC) : a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021 ; 9 : 763-72.
 
35) PRINCIPLE Collaborative Group. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community : interim analyses from the PRINCIPLE trial. medRxiv 2021. 04. 10. 21254672 ; doi : https://doi.org/10.1101/2021.04.10.21254672
 
36) Lenze EJ, et al. Fluvoxamine vs placebo and clinical deterioration in outpatient swith symptomatic COVID-19 : a randomized clinical trial. JAMA. 2020 ; 324 : 2292-300.
 
37) Seftel D, Boulware DR. Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open Forum Infect Dis. 2021 ; 8 : ofab050.
PubMed
38) Horby P, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021 ; 384 : 693-704.
PubMed
39) Beigel JH, et al. Remdesivir for the treatment of Covid-19-final report. N Engl J Med. 2020 ; 383 : 1813-26.
PubMed
40) Pan H, et al. Repurposed antiviral drugs for Covid-19-interim WHO solidarity trial results. N Engl J Med. 2021 ; 384 : 497-511.
PubMed
41) Spinner CD, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19 : a randomized clinical trial. JAMA. 2020 ; 324 : 1048-57.
PubMed
42) Sterne JAC, et al. Association between administration of systemic corticosteroids and mor tality among critically ill patients with COVID-19 : a meta-analysis. JAMA. 2020 ; 324 : 1330-41.
 
43) World Health Organization. Therapeutics and COVID-19 : living guideline (2021/7/6). https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2 [最終アクセス 2021.7.16]
 
44) Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 ; 30 : 269-71.
PubMed
45) Wang Y, et al. Remdesivir in adults with severe COVID-19 : a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 ; 395 : 1569-78.
PubMed
46) Goldman JD, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020 ; 383 : 1827-37.
 
47) Adamsick ML, et al. Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol. 2020 ; 31 : 1384-6.
PubMed
48) Pettit NN, et al. Remdesivir use in the setting of severe renal impairment : a theoretical concern or real risk? Clin Infect Dis. 2020 ; ciaa1851.
PubMed
49) Ackley TW, et al. A valid warning or clinical lore : an evaluation of safety outcomes of remdesivir in patients with impaired renal function from a multicenter matched cohort. Antimicrob Agents Chemother. 2021 ; 65 (2) : e02290-20.
 
50) Joyner MJ, et al. Convalescent plasma antibody levels and the risk of death from covid-19. N Engl J Med. 2021 ; 384 : 1015-27.
PubMed
51) RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial. Lancet. 2021 ; 397 : 2049-59.
 
52) Simonovich VA, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021 ; 384 : 619-29.
PubMed
53) Agarwal A, et al. Convalescent plasma in the management of moderate covid-19 in adults in India : open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020 ; 371 : m3939.
PubMed
54) Chen X, et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin Infect Dis. 2020 ; 71 : 1937-42.
PubMed
55) Herold T, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020 ; 146 : 128-36 e4.
 
56) Del Valle DM, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020 ; 26 : 1636-43.
PubMed
57) Wang Y, et al. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med. 2020 ; 201 : 1430-4.
PubMed
58) Kox M, et al. Cytokine levels in critically ill patients with COVID-19 and other conditions. JAMA. 2020 ; 324 : 1565-7.
PubMed
59) Leisman DE, et al. Cytokine elevation in severe and critical COVID-19 : a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020 ; 8 : 1233-44.
PubMed
60) Stone JH, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020 ; 383 : 2333-44.
PubMed
61) Hermine O, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia : a randomized clinical trial. JAMA Intern Med. 2021 ; 181 : 32-40.
PubMed
62) Salvarani C, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia : a randomized clinical trial. JAMA Intern Med. 2021 ; 181 : 24-31.
PubMed
63) Salama C, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021 ; 384 : 20-30.
PubMed
64) Gordon AC, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021 ; 384 : 1491-502.
PubMed
65) R ECOVERY C ollaborative G roup. Tocilizumab i n patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, openlabel, platform trial. Lancet. 2021 ; 397 : 1637-45.
 
66) Stebbing J, et al. COVID-19 : combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 ; 20 : 400-2.
PubMed
67) Marconi VC, et al. Baricitinib plus standard of care for hospitalized adults with COVID-19. medRxiv 2021.04.30.21255934 ; doi : https://doi.org/10.1101/2021.04.30.21255934
 
68) Kalil AC, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021 ; 384 : 795-807.
PubMed
69) Steinberg KP, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006 ; 354 : 1671-84.
PubMed
70) Meduri GU, et al. Methylprednisolone infusion in early severe ARDS : results of a randomized controlled trial. Chest. 2007 ; 131 : 954-63.
PubMed
71) Ranjbar K, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients : a triple-blinded randomized controlled trial. BMC Infect Dis. 2021 ; 21 : 337.
 
72) Lopez Zuniga M, et al. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response. PLoS One. 2021 ; 16 : e0243964.
PubMed
73) Pinzon MA, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS One. 2021 ; 16 : e0252057.
PubMed
74) Jeronimo CMP, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19 ; Metcovid) : a randomized, double-blind, phase IIb, placebocontrolled trial. Clin Infect Dis. 2021 ; 72 : e373-e81.
PubMed
75) Middeldorp S, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020 ; 18 : 1995-2002.
PubMed
76) Hill JB, et al. Frequency of venous thromboembolism in 6513 patients with COVID-19 : a retrospective study. Blood Adv. 2020 ; 4 : 5373-7.
PubMed
77) Bilaloglu S, et al. Thrombosis in hospitalized patients with COVID-19 in a New York City Health System. JAMA. 2020 ; 324 : 799-801.
 
78) Moll M, et al. VTE in ICU patients with COVID-19. Chest. 2020 ; 158 : 2130-5.
PubMed
79) Cuker A, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 2021 ; 5 : 872-88.
PubMed
80) Sadeghipour P, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mor tality among patients with COVID-19 admitted to the intensive care unit : the INSPIRATION randomized clinical trial. JAMA. 2021 ; 325 : 1620-30.
PubMed
81) Lopes RD, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION) : an open-label, multicentre, randomised, controlled trial. Lancet. 2021 ; 397 : 2253-63.
PubMed
82) Sieswerda E, et al. Recommendations for antibacterial therapy in adults with COVID-19-an evidence based guideline. Clin Microbiol Infect. 2021 ; 27 : 61-6.
PubMed
83) De Waele JJ, et al. Antimicrobial stewardship in ICUs during the COVID-19 pandemic : back to the 90s? Intensive Care Med. 2021 ; 47 : 104-6.
 
84) Mandell LA, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 ; 44 Suppl 2 : S27-72.
 
85) Metlay JP, et al. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 ; 200 : e45-e67.
 
P.64 掲載の参考文献
1) COVID -19 Investigation Team. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020 ; 26 : 861-8.
PubMed
2) Wolfel R, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 ; 581 : 465-9.
PubMed
3) Arons MM, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020 ; 382 : 2081-90.
 
4) Singanayagam A, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. 2020 ; 25 (32) : 2001483.
PubMed
5) He X, et al. Temporal dynamics in viral shedding and transmissibility of COVID -19. Nat Med. 2020 ; 26 : 672-5.
PubMed
6) Ferretti L, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science. 2020 ; 368 (6491) : eabb6936.
PubMed
7) Bullard J, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis. 2020 ; 71 : 2663-6.
PubMed
8) Folgueira MD, et al. Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19. Clin Microbiol Infect. 2021 ; 27 : 886-91.
PubMed
9) Kim MC, et al. Duration of culturable SARS-CoV-2 in hospitalized patients with Covid-19. N Engl J Med. 2021 ; 384 : 671-3.
PubMed
10) van Kampen JJA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat Commun. 2021 ; 12 : 267.
PubMed
11) Cheng HY, et al. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. 2020 ; 180 : 1156-63.
PubMed
12) Rhee C, et al. Duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity : when is it safe to discontinue isolation? Clin Infect Dis. 2021 ; 72 : 1467-74.
PubMed
13) Tarhini H, et al. Long-term severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectiousness among three immunocompromised patients : from prolonged viral shedding to SARS-CoV-2 superinfection. J Infect Dis. 2021 ; 223 : 1522-7.
PubMed
14) Baang JH, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021 ; 223 : 23-7.
 
15) Choi B, et al. Persistence and evolution of SARSCoV-2 in an immunocompromised host. N Engl J Med. 2020 ; 383 : 2291-3.
 
16) Avanzato VA, et al. Case study : prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell. 2020 ; 183 (7) : 1901-1912.e9.
 
17) Aydillo T, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020 ; 383 : 2586-8.
PubMed
18) La Scola B, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020 ; 39 : 1059-61.
PubMed
19) Furukawa NW, et al. Evidence supporting transmission of severe acute respiratory syndrome coronavirus 2 while presymptomatic or asymptomatic. Emerg Infect Dis. 2020 ; 26 (7) : e201595.
PubMed
20) Basile K, et al. Cell-based culture of SARS-CoV-2 informs infectivity and safede-isolation assessments during COVID-19. Clin Infect Dis. 2020 ; ciaa1579.
 
21) Binnicker MJ. Challenges and controversies to testing for COVID-19. J Clin Microbiol. 2020 ; 58 (11) : e01695-20.
PubMed
22) 厚生労働省. 新型コロナウイルス感染症 (COVID-19) 診療の手引き 第5.1版. https://www.mhlw.go.jp/content/000801626.pdf [最終アクセス 2021.7.9]
 
23) Centers for Disease Control and Prevention. Discontinuation of Transmission-Based Precautions and Disposition of Patients with SARS-CoV-2 Infection in Healthcare Settings. https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html [最終アクセス 2021.7.9]
 
24) European Centre for Disease Prevention and Control. Guidance for discharge and ending of isolation of people with COVID-19 (2020.10.16) https://www.ecdc.europa.eu/en/publicationsdata/covid-19-guidance-discharge-and-endingisolation [最終アクセス 2021.7.9]
 
25) WHO. COVID-19 Clinical management : living guidance. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 [最終アクセス 2021.7.9]
 
26) 厚生労働省. 感染症の予防及び感染症の患者に対する医療に関する法律における新型コロナウイルス感染症患者の退院及び就業制限の取扱いについて (一部改正) (2020/6/12). https://www.mhlw.go.jp/content/000639691.pdf [最終アクセス 2021.7.9]
 
27) 厚生労働省. 感染症の予防及び感染症の患者に対する医療に関する法律における新型コロナウイルス感染症患者及び無症状病原体保有者の退院の取扱いに関する質疑応答集 (Q&A) の一部改正について (2020/8/21). https://www.mhlw.go.jp/content/000661925.pdf [最終アクセス 2021.7.9]
 
P.69 掲載の参考文献
1) Nalbandian A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021 ; 27 : 601-15.
PubMed
2) Nasserie T, et al. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19 : a systematic review. JAMA Netw Open. 2021 ; 4 : e2111417.
 
3) Carfi A, et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020 ; 324 : 603-5.
PubMed
4) Garrigues E, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020 ; 81 : e4-e6.
PubMed
5) Miyazato Y, et al. Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infect Dis. 2020 ; 7 : ofaa507.
PubMed
6) Huang C, et al. 6-month consequences of COVID-19 in patients discharged from hospital : a cohort study. Lancet. 2021 ; 397 : 220-32.
 
7) Xiong Q, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China : a single-centre longitudinal study. Clin Microbiol Infect. 2021 ; 27 : 89-95.
 
8) Mo X, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. 2020 ; 55 (6) : 2001217.
PubMed
9) Huang Y, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020 ; 21 : 163.
PubMed
10) Wu X, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation : a prospective study. Lancet Respir Med. 2021 ; 9 : 747-54.
PubMed
11) Myall KJ, et a l. Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021 ; 18 : 799-806.
 
12) Nehme M, et al. COVID-19 symptoms : longitudinal evolution and persistence in outpatient settings. Ann Intern Med. 2021 ; 174 : 723-5.
PubMed
13) Boscolo-Rizzo P, et al. Evolution of altered sense of smell or taste in patients with mildly symptomatic COVID-19. JAMA Otolaryngol Head Neck Surg. 2020 ; 146 : 729-32.
 
14) Logue JK, et al. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. 2021 ; 4 : e210830.
PubMed
15) Blomberg B, et al. Long COVID in a prospective cohort of home-isolated patients. Nat Med. 2021. doi : 10.1038/s41591-021-01433-3.
 
16) Taquet M, et al. Bidirectional associations between COVID-19 and psychiatric disorder : retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021 ; 8 : 130-40.
PubMed
17) Halpin SJ, et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection : a cross-sectional evaluation. J Med Virol. 2021 ; 93 : 1013-22.
PubMed
18) Morin L, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA. 2021 ; 325 : 1525-34.
PubMed
19) Del Brutto OH, et al. Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection : a longitudinal prospective study nested to a population cohort. Eur J Neurol. 2021 ; 10.1111/ene.14775.
 
P.74 掲載の参考文献
1) Meyerowitz EA, et al. Transmission of SARS-CoV-2 : a review of viral, host, and environmental factors. Ann Intern Med. 2021 ; 174 : 69-79.
PubMed
2) Centers for Disease Control and Prevention. Scientific Brief : SARS - CoV-2 Transmission. (2021/5/7) https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html [最終アクセス 2021.7.12]
 
3) World Health Organization. Coronavirus disease (COVID-19) : How is it transmitted? (2020/12/13) https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19-how-is-it-transmitted [最終アクセス 2021.7.12]
 
4) World Health Organization. Transmission of SARS-CoV-2 : implications for infection prevention precautions. Scientific Brief. (2020/7/9) https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-forinfection-prevention-precautions [最終アクセス 2021.7.12]
 
5) Kurosu H, et al. Possible contact transmission of SARS-CoV-2 in healthcare settings in Japan, 2020 -2021. Infect Control Hosp Epidemiol. 2021 : 1-12.
 
6) Greenhalgh T, et al. Ten scientific reasons in support of airborne transmission of SARS-CoV-2. Lancet. 2021 ; 397 : 1603-5.
PubMed
7) Nishiura H, et al. Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19). medRxiv 2020.02.28.20029272.
 
8) Guo ZD, et al. Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards, Wuhan, China, 2020. Emerg Infect Dis. 2020 ; 26 : 1583-91.
PubMed
9) Lednicky JA, et al. Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients. Int J Infect Dis. 2020 ; 100 : 476-82.
PubMed
10) Liu Y, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature. 2020 ; 582 : 557-60.
PubMed
11) van Doremalen N, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020 ; 382 : 1564-7.
PubMed
12) Lu J, et al. COVID-19 outbreak associated with air conditioning in restaurant, Guangzhou, China, 2020. Emerg Infect Dis. 2020 ; 26 : 1628-31.
PubMed
13) Hamner L, et al. High SARS-CoV-2 attack rate following exposure at a Choir Practice-Skagit County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020 ; 69 : 606-10.
 
14) Jang S, et al. Cluster of coronavirus disease associated with fitness dance classes, South Korea. Emerg Infect Dis. 2020 ; 26 : 1917-20.
PubMed
15) Park SY, et al. Coronavirus disease outbreak in call center, South Korea. Emerg Infect Dis. 2020 ; 26 : 1666-70.
PubMed
16) de Man P, et al. Outbreak of coronavirus disease 2019 (COVID-19) in a nursing home associated with aerosol transmission as a result of inadequate ventilation. Clin Infect Dis. 2021 ; 73 : 170-1.
 
17) Shen Y, et al. Community outbreak investigation of SARS-CoV-2 transmission among bus riders in Eastern China. JAMA Intern Med. 2020 ; 180 : 1665-71.
PubMed
18) Centers for Disease Control and Prevention. Clinical Questions about COVID-19 : Questions and Answers. Which procedures are considered aerosol generating procedures in healthcare settings? https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html [最終アクセス 2021.7.12]
 
19) World Health Organization. Infection prevention and control during health care when coronavirus disease (COVID-19) is suspected or confirmed. (2021/7/12) https://www.who.int/publications/i/item/WHO-2019-nCoV-IPC-2021.1 [最終アクセス 2021.7.12]
 
20) Klompas M, et al. What is an aerosol-generating procedure? JAMA Surg. 2021 ; 156 : 113-4.
PubMed
21) Ong SWX, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020 ; 323 : 1610-2.
PubMed
22) Wang H, et al. Environmental virus surveillance in the isolation ward of COVID-19. J Hosp Infect. 2020 ; 105 : 373-4.
PubMed
23) Ahn JY, et al. Environmental contamination in the isolation rooms of COVID-19 patients with severe pneumonia requiring mechanical ventilation or high-flow oxygen therapy. J Hosp Infect. 2020 ; 106 : 570-6.
PubMed
24) Nakamura K, et al. Environmental surface and air contamination in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patient rooms by disease severity. Infection Prevention in Practice 2020 ; 2 (4) : 100098.
PubMed
25) Chin AWH, et al. Stability of SARS-CoV-2 in different environmental conditions. Lancet Microbe. 2020 ; 1 : e10.
PubMed
26) World Health Organization. WHO guidelines on hand hygiene in health care. https://www.who.int/publications/i/item/9789241597906 [最終アクセス 2021.7.12]
 
27) Hirose R, et al. Survival of SARS-CoV-2 and influenza virus on the human skin : importance of hand hygiene in COVID-19. Clin Infect Dis. 2020 ; ciaa1517.
 
28) Ferretti L, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science. 2020 ; 368 (6491) : eabb6936.
PubMed
29) Centers for Disease Control and Prevention. Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic. (2021/2/23) https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-controlrecommendations.html [最終アクセス 2021.7.12]
 
30) Lee JK, Jeong HW. Wearing face masks regardless of symptoms is crucial for preventing the spread of COVID -19 in hospitals. Infect Control Hosp Epidemiol. 2021 ; 42 : 115-6.
PubMed
31) 一般社団法人日本環境感染学会. 医療機関における新型コロナウイルス感染症への対応ガイド 第3版 (2020.5.8). http://www.kankyokansen.org/modules/news/index.php?content_id=355 [最終アクセス 2021.7.12]
 
32) Wang X, et al. Association between universal masking in a health care system and SARS-CoV-2 positivity among health care workers. JAMA. 2020 ; 324 : 703-4.
 
33) Centers for Disease Control and Prevention. Science Brief : Community Use of Cloth Masks to Control the Spread of SARS-CoV-2. (2021/5/7) https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html [最終アクセス 2021.7.12]
 
34) Leung NHL, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med. 2020 ; 26 : 676-80.
PubMed
35) Fischer EP, et al. Low-cost measurement of face mask efficacy for filtering expelled droplets during speech. Sci Adv. 2020 ; 6 (36) : eabd3083.
PubMed
36) Doung-Ngern P, et al. Case-control study of use of personal protective measures and risk for SARS-CoV 2 infection, Thailand. Emerg Infect Dis. 2020 ; 26 : 2607-16.
PubMed
37) Payne DC, et al. SARS-CoV-2 infections and serologic responses from a sample of U. S. Navy Service Members-USS Theodore Roosevelt, April 2020. MMWR Morb Mortal Wkly Rep. 2020 ; 69 : 714-21.
 
38) Chu DK, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19 : a systematic review and meta-analysis. Lancet. 2020 ; 395 : 1973-87.
PubMed
39) Zeng W, et al. Association of daily wear of eyeglasses with susceptibility to coronavirus disease 2019 infection. JAMA Ophthalmol. 2020 ; 138 : 1196-9.
PubMed
40) Bhaskar ME, Arun S. SARS- CoV-2 infection among community health workers in India before and after use of face shields. JAMA. 2020 ; 324 : 1348-9.
PubMed
41) Wong LY, et al. Healthcare workers in Singapore infected with COVID-19 : 23 January-17 April 2020. Influenza Other Respir Viruses. 2021 ; 15 : 218-26.
PubMed
42) Steensels D, et al. Hospital-wide SARS-CoV-2 antibody screening in 3056 staff in a tertiary center in Belgium. JAMA. 2020 ; 324 : 195-7.
 
43) 新型コロナウイルス感染症対策分科会. 分科会から政府への提言. 感染リスクが高まる「5つの場面」と「感染リスクを下げながら会食を楽しむ工夫」 (2020/10/23). https://www.cas.go.jp/jp/seisaku/ful/bunkakai/teigen_12_1.pdf [最終アクセス 2021.7.12]
 
44) Cheng HY, et al. Contact tracing assessment of COVID-19 transmission dynamics in Taiwan and risk at different exposure periods before and after symptom onset. JAMA Intern Med. 2020 ; 180 : 1156-63.
PubMed
45) Rosenberg ES, et al. COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York State-March 2020. Clin Infect Dis. 2020 ; 71 : 1953-9.
PubMed
46) Wu J, et al. Household transmission of SARS-CoV-2, Zhuhai, China, 2020. Clin Infect Dis. 2020 ; 71 : 2099-108.
PubMed
47) Li W, et al. Characteristics of household transmission of COVID-19. Clin Infect Dis. 2020 ; 71 : 1943-6.
PubMed
48) Fung HF, et al. The household secondary attack rate of SARS-CoV-2 : a rapid review. Clin Infect Dis. 2020 ; ciaa1558.
PubMed
49) Bohmer MM, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case : a case series. Lancet Infect Dis. 2020 ; 20 : 920-8.
 
50) Bi Q, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China : a retrospective cohort study. Lancet Infect Dis. 2020 ; 20 : 911-9.
 
51) Ng OT, et al. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts : a retrospective cohort study. Lancet Infect Dis. 2021 ; 21 : 333-43.
PubMed
52) Wang Y, et al. Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing : a cohort study in Beijing, China. BMJ Glob Health. 2020 ; 5 (5) : e002794.
PubMed
P.88 掲載の参考文献
1) 一般社団法人日本感染症学会ワクチン委員会. COVID-19ワクチンに関する提言 第3版. https://www.kansensho.or.jp/modules/guidelines/index.php?content_id=43 [最終アクセス 2021.7.21]
 
2) 厚生労働省. 希望する高齢者に対する新型コロナワクチン接種. https://www.mhlw.go.jp/stf/newpage_19331.html [最終アクセス 2021.7.21]
 
3) 内閣官房. 政府CIOポータル. 新型コロナワクチンの接種状況. https://cio.go.jp/c19vaccine_dashboard [最終アクセス 2021.7.21]
 
4) Our World In Data. Coronavirus (COVID-19) Vaccinations. https://ourworldindata.org/covidvaccinations [最終アクセス 2021.7.21]
 
5) Cagigi A, Lore K. Immune responses induced by mRNA vaccination in mice, monkeys and humans. Vaccines (Basel). 2021 ; 9 (1) : 61.
PubMed
6) Bettini E, Locci M. SARS-CoV-2 mRNA vaccines : immunological mechanism and beyond. Vaccines (Basel). 2021 ; 9 (2) : 147.
PubMed
7) COVID-19 Real-Time Learning Network. Vaccines FAQ. https://www.idsociety.org/covid-19-realtime-learning-net work/vaccines/vaccinesinformation--faq/ [最終アクセス 2021.7.21]
 
8) Centers for Disease Control and Prevention (U. S.). Administer the Vaccine (s). https://www.cdc.gov/vaccines/hcp/admin/administervaccines.html [最終アクセス 2021.7.21])
 
9) Nakajima Y, et al. Establishing a new appropriate intramuscular injection site in the deltoid muscle. Hum Vaccin Immunother. 2017 ; 13 : 2123-9.
PubMed
10) 奈良県立医科大学臨床研修センター. 筋肉注射手技マニュアル v1.7. https://www.nmu-resident.jp/info/files/intramuscular17.pdf [最終アクセス 2021.7.21]
 
11) 日本プライマリ・ケア連合学会ワクチンチーム. 新型コロナワクチン-より安全な新しい筋注の方法2021年3月版. https://www.youtube.com/watch?v=tA96CA6fJv8 [最終アクセス 2021.7.21]
 
12) Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html [最終アクセス 2021.7.21]
 
13) Parry H, et al. Extended interval BNT162b2 vaccination enhances peak antibody generation in older people. medRxiv 2021.05.15.21257017 ; doi : https://doi.org/10.1101/2021.05.15.21257017.
 
14) コミナティ筋注 (添付文書). https://www.info.pmda.go.jp/go/pack/631341DA1025_1_03/ [最終アクセス 2021.7.21]
 
15) Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020 ; 383 : 2603-15.
PubMed
16) Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 ; 384 : 403-16.
PubMed
17) Dagan N, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021 ; 384 : 1412-23.
 
18) Haas EJ, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel : an observational study using national sur veillance data. L ancet. 2021 ; 397 : 1819-29.
 
19) Pilishvili T, et al. Interim estimates of vaccine effectiveness of Pfizer-BioNTech and Moderna COVID-19 vaccines among health care personnel-33 U. S. Sites, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021 ; 70 : 753-8.
PubMed
20) Benenson S, et al. BNT162b2 mRNA Covid-19 vaccine ef fectiveness among health care workers. N Engl J Med. 2021 ; 384 : 1775-7.
 
21) Daniel W, et al. Early evidence of the Effect of SARS-CoV-2 vaccine at one medical center. N Engl J Med. 2021 ; 384 : 1962-3.
 
22) Angel Y, et al. Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers. JAMA. 2021 ; 325 : 2457-65.
PubMed
23) Amit S, et al. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. Lancet. 2021 ; 397 : 875-7.
PubMed
24) Hall VJ, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN) : a prospective, multicentre, cohort study. Lancet. 2021 ; 397 : 1725-35.
 
25) Shrotri M, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI) : a prospective cohort study. Lancet Infect Dis. 2021 ; S1473-3099 (21) 00289-9.
 
26) Thompson MG, et al. Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021 ; NEJMoa2107058.
PubMed
27) Bernal JR, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021 ; 385 (7) : 585-94.
 
28) Keehner J, et al. SARS-CoV-2 infection after vaccination in health care workers in California. N Engl J Med. 2021 ; 384 : 1774-5.
PubMed
29) Thompson MG, et al. Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers-eight U. S. locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 ; 70 : 495-500.
PubMed
30) COVID-19 vaccine breakthrough infections reported to CDC - United States, January 1-April 30, 2021. MMWR Morb Mor tal Wkly Rep. 2021 ; 70 : 792-3.
 
31) COVID Symptom Study. Cases rising rapidly among those with incomplete vaccinations (6/10/2021). https://covid.joinzoe.com/post/cases-rising-rapidly-among-those-with-incomplete-vaccinations [最終アクセス 2021.7.21]
 
32) Levine-Tiefenbrun M, et al. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021 ; 27 : 790-2.
PubMed
33) Harris RJ, et al. Ef fect of vaccination on household transmission of SARS-CoV-2 in England. N Engl J Med. 2021 ; NEJMc2107717.
 
34) Teran RA, et al. Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members-Chicago, Illinois, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 ; 70 : 632-8.
PubMed
35) Monin L, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer : interim analysis of a prospective observational study. Lancet Oncol. 2021 ; 22 : 765-78.
PubMed
36) Massarweh A, et al. Evaluation of seropositivity following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. JAMA Oncol. 2021 ; e212155.
PubMed
37) Maneikis K, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania : a national prospective cohort study. Lancet Haematol. 2021 ; S2352-3026 (21) 00169-1.
 
38) Herishanu Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021 ; 137 : 3165-73.
PubMed
39) Tsapepas D, et al. Clinically significant COVID-19 following SARS-CoV-2 vaccination in kidney transplant recipients. Am J Kidney Dis. 2021 ; S0272-6386 (21) 00621-1.
 
40) Kamar N, et al. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021 ; NEJMc2108861.
PubMed
41) Saadat S, et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021 ; 325 : 1467-9.
PubMed
42) Krammer F, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021 ; 384 : 1372-4.
PubMed
43) Leidi A, et al. Risk of reinfection after seroconversion to SARS-CoV-2 : A population-based propensity-score matched cohort study. Clin Infect Dis. 2021 ; ciab495.
PubMed
44) Hall VJ, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibodynegative health-care workers in England : a large, multicentre, prospective cohort study (SIREN) Lancet. 2021 ; 397 : 1459-69.
 
45) Lumley SF, et al. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med. 2021 ; 384 : 533-40.
PubMed
46) Jeffery-Smith A, et al. Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020. Euro Sur veill. 2021 ; 26 (5) : 2100092.
 
47) Harvey RA, et al. Association of SARS-CoV-2 seropositive antibody test with risk of future infection. JAMA Intern Med. 2021 ; 181 : 672-9.
PubMed
48) Abu-Raddad LJ, et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. E Clinical Medicine. 2021 ; 35 : 100861.
 
49) Vitale J, et al. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy. JAMA Intern Med. 2021 ; e212959.
 
50) Lustig Y, et al. Neutralizing response against variants after SARS-CoV-2 infection and one dose of BNT162b2. N Engl J Med. 2021 ; 384 : 2453-4.
PubMed
51) Liu Y, et al. BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants. N Engl J Med. 2021 ; NEJMc2106083.
PubMed
52) Miyakawa K, et al. Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera. medRxiv 2021.05.06.21256788 ; doi : https://doi.org/10.1101/2021.05.06.21256788.
 
53) Abu-Raddad LJ, et al. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021 ; 385 (2) : 187-189.
 
54) Israel data reportedly shows drop in efficacy of Pfizer-BioNTech vaccine as delta variant spreads. https://fortune.com/2021/07/05/israel-data-plunge-efficacy-pfizer-biontechvaccine-delta-variant/ [最終アクセス 2021.7.21]
 
55) Frenck RW Jr, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021 ; 385 (3) : 239-250.
PubMed
56) 日本小児科学会. 新型コロナワクチン～子どもならびに子どもに接する成人への接種に対する考え方～. http://www.jpeds.or.jp/modules/activity/index.php?content_id=374 [最終アクセス 2021.7.21]
 
57) Gray KJ, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women : a cohort study. Am J Obstet Gynecol. 2021 ; S0002-9378 (21) 00187-3.
 
58) Collier AY, et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA. 2021 ; 325 : 2370-80.
PubMed
59) Paul G, Chad R. Newborn antibodies to SARS-CoV-2 detected in cord blood after maternal vaccination-a case report. BMC Pediatr. 2021 ; 21 : 138.
PubMed
60) Gill L, Jones CW. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in neonatal cord blood after vaccination in pregnancy. Obstet Gynecol. 2021 ; 137 : 894-6.
PubMed
61) Shimabukuro TT, et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021 ; 384 : 2273-82.
 
62) 日本産婦人科学会. 妊産婦のみなさまへ-新型コロナウイルス (メッセンジャーRNA) ワクチンについて- (2021.6.17). http://www.jsog.or.jp/news/pdf/20210617_COVID19.pdf [最終アクセス 2021.7.21]
 
63) Perl SH, et al. SARS-CoV-2-specific antibodies in breast milk after COVID -19 vaccination of breastfeeding women. JAMA. 2021 ; 325 : 2013-4.
PubMed
64) Kelly JC, et al. Anti-severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination. Am J Obstet Gynecol. 2021 ; 225 : 101-3.
PubMed
65) ファイザー社 Webサイト. https://www.pfizer.com/news/press-release/press-release-detail/pfizerand-biontech-confirm-high-efficacy-and-noserious [最終アクセス 2021.7.21]
 
66) Doria-Rose N, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021 ; 384 : 2259-61.
PubMed
67) 厚生労働省. 新型コロナワクチン Q&A. https://www.cov19-vaccine.mhlw.go.jp/qa/0019.html [最終アクセス 2021.7.21]
 
68) Milman O, et al. Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals. Nat Med. 2021. doi : 10.1038/s41591-021-01407-5.
 
69) Chapin-Bardales J, et al. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021 ; 325 : 2201-2.
PubMed
70) Menni C, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK : a prospective observational study. Lancet Infect Dis. 2021 ; 21 : 939-49.
 
71) d'Arminio Monforte A, et al. Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination : data from 3,078 health care workers. E Clinical Medicine. 2021 ; 36 : 100914.
 
72) Ebinger JE, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021 ; 27 : 981-4.
 
73) Waissengrin B, et al. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 2021 ; 22 : 581-3.
PubMed
74) Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 2021 ; 325 : 780-1.
PubMed
75) Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine-United States, December 14-23, 2020. MMWR Morb Mortal Wkly Rep. 2021 ; 70 : 46-51.
PubMed
76) Shimabukuro TT, et al. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021. JAMA. 2021 ; 325 : 1101-2.
PubMed
77) 第61回厚生科学審議会予防接種・ワクチン分科会副反応検討部会. 副反応疑い報告の状況について. https://www.mhlw.go.jp/content/10906000/000791617.pdf [最終アクセス 2021.7.21]
 
78) Blumenthal KG, et al. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021 ; 325 : 1562-5.
PubMed
79) Blumenthal KG, et al. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med. 2021 ; 384 : 1273-7.
PubMed
80) Johnston MS, et al. Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine : a case series. JAMA Dermatol. 2021 ; 157 : 716-20.
 
81) McMahon DE, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination : a registry-based study of 414 cases. J Am Acad Dermatol. 2021 ; 85 : 46-55.
 
82) Becker AS, et al. Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging : radiology scientific expert panel. Radiology. 2021 : 210436.
 
83) Adin ME, et al. Association of COVID-19 mRNA vaccine with ipsilateral axillary lymph node reactivity on imaging. JAMA Oncol. 2021 ; e211794.
PubMed
84) Cohen D, et al. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine : incidence assessed by [18F] FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging. 2021 ; 48 : 1854-63.
PubMed
85) Keshavarz P, et al. Lymphadenopathy following COVID-19 vaccination : imaging findings review. Acad Radiol. 2021 ; S1076-6332 (21) 00196-3.
 
86) Fleury V, et al. COVID-19 vaccination may cause FDG uptake beyond axillary area. Eur J Hybrid Imaging. 2021 ; 5 : 11.
PubMed
87) Society of Breast Imaging Patient Care and Delivery Committee. SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination. https://www.sbi-online.org/Portals/0/Position%20Statements/2021/SBI-recommendations-for-managing-axillary-adenopathy-post-COVID-vaccination.pdf [最終アクセス 2021.7.21]
 
88) Montgomery J, et al. Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US Military. JAMA Cardiol. 2021 ; e212833.
PubMed
89) Gargano JW, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients : update from the Advisory Committee on Immunization Practices-United States, June 2021. MMWR Morb Mortal Wkly Rep. ePub : 6 July 2021. DOI : http://dx.doi.org/10.15585/mmwr.mm7027e2external
 
90) Abu Mouch S, et al. Myocarditis following COVID-19 mRNA vaccination. Vaccine. 2021 ; 39 : 3790-3.
PubMed
91) Marshall M, et al. Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination. Pediatrics. 2021 ; e2021052478.
 
92) Muthukumar A, et al. In depth evaluation of a case of presumed myocarditis following the second dose of COVID-19 mRNA vaccine. Circulation. 2021. doi : 10.1161/CIRCULATIONAHA.121.056038.
 
93) Bautista Garcia J, et al. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. Rev Esp Cardiol. 2021. doi : 10.1016/j.recesp.2021.03.009.
 
94) O'Leary ST, Maldonado YA. Myocarditis after SARS-CoV-2 vaccination : true, true, and…related? Pediatrics. 2021 ; e2021052644.
 
95) Mele D, et al. Myocarditis in COVID-19 patients : current problems. Intern Emerg Med. 2021 ; 16 (5) : 1123-1129.
PubMed
96) Daniels CJ, et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection : results from the Big Ten COVID-19 Cardiac Registry. JAMA Cardiol. 2021 ; e212065.
PubMed
97) Gonzalez DC, et al. Sperm parameters before and after COVID-19 mRNA vaccination. JAMA. 2021. doi : 10.1001/jama.2021.9976.
 
98) Gacci M, et al. Semen impairment and occurrence of SARS-CoV-2 virus in semen after recovery from COVID-19. Hum Reprod. 2021 ; 36 : 1520-9.
PubMed
99) 第61回厚生科学審議会予防接種・ワクチン分科会副反応検討部会. 副反応疑い報告の状況について. https://www.mhlw.go.jp/content/10906000/000791617.pdf [最終アクセス 2021.7.21]
 
100) Torjesen I. Covid-19 : Norway investigates 23 deaths in frail elderly patients after vaccination. BMJ. 2021 ; 372 : n149.
PubMed
101) Centers for Disease Control and prevention. Choosing Safer Activities. https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/participate-in-activities.html [最終アクセス 2021.7.21]
 
102) Centers for Disease Control and prevention. Domestic Travel During COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/travelers/travelduring-covid19.html [最終アクセス 2021.7.21]
 
103) Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 ; 397 : 99-111.
PubMed
104) Voysey M, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine : a pooled analysis of four randomised trials. Lancet. 2021 ; 397 : 881-91.
PubMed
105) World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience). https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1 [最終アクセス 2021.7.21]
 
106) Vasileiou E, et al. Interim findings from firstdose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland : a national prospective cohort study. Lancet. 2021 ; 397 : 1646-57.
 
107) Emary KRW, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7) : an exploratory analysis of a randomised controlled trial. Lancet. 2021 ; 397 : 1351-62.
PubMed
108) Madhi SA, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021 ; 384 : 1885-98.
 
109) JCVI advises on COVID-19 vaccine for people aged under 40. https://www.gov.uk/government/news/jcvi-advises-on-covid-19-vaccine-for-people-aged-under-40 [最終アクセス 2021.7.21]
 
110) Schultz NH, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021 ; 384 : 2124-30.
PubMed
111) Greinacher A, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021 ; 384 : 2092-101.
PubMed
112) Scully M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021 ; 384 : 2202-11.
PubMed
113) Cines DB, Bussel JB. SARS-CoV-2 vaccineinduced immune thrombotic thrombocytopenia. N Engl J Med. 2021 ; 384 : 2254-6.
PubMed
114) Furie KL, et al. Diagnosis and management of cerebral venous sinus thrombosis with vaccineinduced immune thrombotic thrombocytopenia. Stroke. 2021 ; 52 : 2478-82.
PubMed
115) Bourguignon A, et al. Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia. N Engl J Med. 2021. doi : 10.1056/NEJMoa2107051.
 
116) 日本脳卒中学会/日本血栓止血学会. アストラゼネカ社COVID-19 ワクチン接種後の血小板減少症を伴う血栓症の診断と治療の手引き 第2版 (2021/6). https://www.jsts.gr.jp/news/pdf/20210601_tts2_3.pdf [最終アクセス 2021.7.21]
 
117) Allen CM, et al. Guillain-Barre syndrome variant occurring after SARS-CoV-2 vaccination. Ann Neurol. 2021. doi : 10.1002/ana.26144.
 
118) Maramattom BV, et al. Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine. Ann Neurol. 2021. doi : 10.1002/ana.26143.
 
119) Dyer O. Covid-19 : EMA defends AstraZeneca vaccine as Germany and Canada halt rollouts. BMJ. 2021 ; 373 : n883.
PubMed
120) Borobia AM, et al . Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS) : a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021 ; 398 (10295) : 121-130.
PubMed
121) Sadoff J, et al. Safety and efficacy of singledose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021 ; 384 : 2187-201.
PubMed
122) Muir KL, et al. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021 ; 384 : 1964-5.
PubMed
123) See I, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA. 2021 ; 325 : 2448-56.
PubMed
124) Centers for Disease Control and prevention. CDC Recommends Use of Johnson & Johnson's Janssen COVID-19 Vaccine Resume. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html [最終アクセス 2021.7.21]
 
125) National Comprehensive Cancer Net work. Recommendations of the NCCN COVID-19 Vaccination Advisory Committee (Version 3.0 06/9/2021). https://www.nccn.org/docs/defaultsource/covid-19/2021_covid-19_vaccination_guidance_v2-0.pdf?sfvrsn=b483da2b_2 [最終アクセス 2021.7.21]
 
126) Royal College of Surgeons of England. Vaccinated patients guidance. https://www.rcseng.ac.uk/coronavirus/vaccinated-patientsguidance/ [最終アクセス 2021.7.21]
 
127) Memorial Sloan Kettering Cancer Center. MSK COVID-19 VACCINE INTERIM GUIDELINES FOR CANCER PATIENTS. https://www.asco.org/sites/new-www.asco.org/files/content-files/covid-19/2021-MSK-COVID19-VACCINE-GUIDELINES.pdf [最終アクセス 2021.7.21]
 
128) Arnold J, et al. COVID -19 vaccination and antirheumatic therapy. Rheumatology (Oxford). 2021 ; keab223.
PubMed
129) American College of Rheumatology. COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases. https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf [最終アクセス 2021.7.21]
 

Part 2 新型コロナウイルス感染症対策の実際

P.118 掲載の参考文献
1) 新型コロナウイルス感染症 (COVID-19) 診療の手引き 第5版. https://www.mhlw.go.jp/content/000785119.pdf [最終アクセス 202.6.25]
 
2) NEJM Procedure. Collection of Nasopharyngeal Specimens with the Swab Technique.https://www.youtube.com/watch?v=DVJNWefmHjE [最終アクセス 202.6.25]
 
P.125 掲載の参考文献
1) IASC (Inter-Agency Standing Committee). Interim Briefing Note Addressing Mental Health and Psychosocial Aspects of COVID-19 Outbreak. Version 1.5, 2020. https://interagencystandingcommittee.org/iasc-reference-group-mental-health-andpsychosocial-support-emergency-settings/interimbriefing [最終アクセス 2021.7.19]
 
2) van Doremalen N, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. NEJM. 2020 ; 382 (16) : 1564-7.
PubMed
3) Chu DK, et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19 : a systematic review and meta-analysis. Lancet. 2020 ; 395 (10242) : 1973-87.
PubMed
P.132 掲載の参考文献
1) Vaughn VM, et al. Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) : A Multi-hospital Cohort Study. Clin Infect Dis. 2021 ; 72 (10) : e533-e541.
PubMed
2) Rawson TM, et al. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect. 2021 ; 27 (1) : 9-11.
PubMed
3) Garcia-Vidal C, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19 : a retrospective cohort study. Clin Microbiol Infect. 2021 ; 27 (1) : 83-8.
PubMed
4) Kolenda C, et al. Assessment of Respiratory Bacterial Coinfections Among Severe Acute Respiratory Syndrome Coronavirus 2-Positive Patients Hospitalized in Intensive Care Units Using Conventional Culture and BioFire, FilmArray Pneumonia Panel Plus Assay. Open Forum Infect Dis. 2020 ; 7 (11) : ofaa484.
PubMed
5) Lansbury L, et al. Co-infections in people with COVID-19 : a systematic review and meta-analysis. J Infect. 2020 ; 81 (2) : 266-75.
PubMed
6) Langford BJ, et al. Bacterial co-infection and secondary infection in patients with COVID-19 : a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 ; 26 (12) : 1622-9.
PubMed
7) Somers EC, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2021 ; 73 (2) : e445-e454.
PubMed
8) Gupta S, et al. Association Bet ween Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. JAMA Intern Med. 2021 ; 181 (1) : 41-51.
 
9) Sieswerda E, et al. Recommendations for antibacterial therapy in adults with COVID-19-an evidence based guideline. Clin Microbiol Infect. 2021 ; 27 (1) : 61-6.
PubMed
10) Wang W, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020 ; 323 (18) : 1843-4.
PubMed
11) Xiao F, et al. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. Emerg Infect Dis. 2020 ; 26 (8) : 1920-2.
PubMed
12) Kang M, et al. Probable Evidence of Fecal Aerosol Transmission of SARS-CoV-2 in a High-Rise Building. Ann Intern Med. 2020 ; 173 (12) : 974-80.
 
P.142 掲載の参考文献
1) 神戸市市立医療センター中央市民病院. 新型コロナウイルス感染症の院内感染に関する報告書 (2020年8月7日). http://chuo.kcho.jp/news/2020-08-07 [最終アクセス 2021.6.28]
 
2) Jianyun Lu, et al. COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020. Emerg Infect Dis 2020 ; 26 : 1628-31.
PubMed
3) Ferretti L, et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science. 2020 ; 368 (6491) : eabb6936.
PubMed
4) Wolfel R, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 ; 581 (7809) : 465-9.
PubMed
5) van Kampen JJA, et al. Duration and key determinants of infectious virus shedding in hospitalized patient swith corona virus disease-2019 (COVID-19). Nat Commun. 2021 ; 12 (1) : 267.
 
6) 日本環境感染学会. 医療機関における新型コロナウイルス感染症への対応ガイド 第3版. http://www.kankyokansen.org/uploads/uploads/files/jsipc/COVID-19_taioguide3.pdf [最終アクセス 2021.6.28]
 
7) Centers for Disease Control and Prevention. Interim U. S. Guidance for Risk Assessment and Work Restrictions for Healthcare Personnel with Potential Exposure to SARS-CoV-2. https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidancerisk-assesment-hcp.html [最終アクセス 2021.6.28]
 
P.148 掲載の参考文献
1) 神戸市ホームページ. 新型コロナウイルス感染症の検査や受診, 入院から退院の流れ. https://www.city.kobe.lg.jp/documents/38783/06_flowchart_honninshoujouari.pdf [最終アクセス 2021.6.16
 
P.159 掲載の参考文献
1) Lei S, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. E Clinical Medicine. 2020 ; 21 : 100331
 
2) COVIDSurg Collaborative ; GlobalSurg Collaborative. Timing of surgery following SARS-CoV-2 infection : an international prospective cohort study. Anaesthesia. 2021 ; 76 (6) : 748-58.
 
3) COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection : an international cohort study. Lancet. 2020 ; 396 (10243) : 27-38.
 
P.161 掲載の参考文献
1) Lei S, et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection. EClinicalMedicine. 2020 ; 21 : 100331
PubMed
2) COVIDSurg Collaborative ; GlobalSurg Collaborative. Timing of surgery following SARS-CoV-2 infection : an international prospective cohort study. Anaesthesia. 2021 ; 76 (6) : 748-58.
 
3) COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection : an international cohort study. Lancet. 2020 ; 396 (10243) : 27-38.
 
4) Yang K, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China : a multicentre, retrospective, cohort study. Lancet Oncol. 2020 ; 21 (7) : 904-13.
 
5) Robilotti EV, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020 ; 26 (8) : 1218-23.
PubMed
P.170 掲載の参考文献
1) 厚生労働省. 新型コロナウイルス感染症診療の手引き. 第5版. https://www.mhlw.go.jp/content/000815065.pdf [最終アクセス 2021.7.30]]
 
2) Berlin DA, et al. Severe Covid-19. N Engl J Med. 2020 ; 383 (25) : 2451-60.
PubMed
3) Armstrong R A, et al. Mor tality in patients admitted to intensive care with COVID-19 : an updated systematic review and meta-analysis of observational studies. Anaesthesia. 2021 ; 76 (4) : 537-48.
 
4) National Institutes of Health, Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/ [最終アクセス 2021.6.13]
 
5) Centers for Disease Control and Prevention, Underlying Medical Conditions Associated with High Risk for Severe COVID-19 : Information for Healthcare Providers (Updated May 13, 2021) https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html [最終アクセス 2021.6.13]
 
6) WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19 : A Meta-analysis. JAMA. 2020 ; 324 (13) : 1330-41.
 
7) RECOVERY Collaborative Group, Horby P, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 ; 384 (8) : 693-704.
 
8) Ranjbar K, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients : a triple-blinded randomized controlled trial. BMC Infect Dis. 2021 ; 21 (1) : 337.
 
9) Edalatifard M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients : results from a randomised controlled clinical trial. Eur Respir J. 2020 ; 56 (6) : 2002808.
PubMed
10) Beigel JH, et al. Remdesivir for the Treatment of Covid-19-Final Report. N Engl J Med. 2020 ; 383 (19) : 1813-26.
 
11) Salama C, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021 ; 384 (1) : 20-30.
PubMed
12) REMAP-CAP Investigators, Gordon AC, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021 ; 384 (16) : 1491-1502.
PubMed
13) RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, openlabel, platform trial. Lancet. 2021 ; 397 (10285) : 1637-45.
 
14) Rosas IO, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021 ; 384 (16) : 1503-16.
PubMed
15) Stone JH, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid -19. N Engl J Med. 2020 ; 383 (24) : 2333-44.
PubMed
16) Rentsch CT, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States : cohort study. BMJ. 2021 ; 372 : n311.
PubMed
17) The REMAP-CAP, ACTIV-4a, and ATTACC Investigators. Therapeutic Anticoagulation in Critically Ill Patients with Covid-19- Preliminary Report. MedRxiv. 03.10.21252749, 2021.
 
18) Kalil AC, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021 ; 384 (9) : 795-807.
PubMed
19) Marconi VC, et al. Efficacy and safety of baricitinib in patients with COVID-19 infection : Results from the randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial. MedRxiv. 04.30.21255934, 2021.
 
P.173 掲載の参考文献
1) Ferreyro BL, et al. Association of noninvasive oxygenation strategies with all-cause mortality in adults with acute hypoxemic respiratory failure : A systematic review and meta-analysis. JAMA. 2020 ; 324 (1) : 57-67.
PubMed
2) 日本Covid-19対策ECMO-net. COVID-19関連重症者の人工呼吸管理. v1.4. 2020/03/10 https://www.jsicm.org/news/upload/COVID-19-ECMOnetreport_20200310.pdf [2021/6/18 アクセス時]
 
3) Gaeckle NT, et al. Aerosol generation from the respiratory tract with various modes of oxygen Delivery. Am J Respir Crit Care Med. 2020 ; 202 (8) : 1115-24.
PubMed
4) Ferioli M. et al. Protecting healthcare workers from SARS-CoV-2 infection : practical indications. Eur Respir Rev. 2020 ; 29 (155) : 200068.
PubMed
P.175 掲載の参考文献
1) Ferreyro BL, et al. Association of noninvasive oxygenation strategies with all-cause mortality in adults with acute hypoxemic respiratory failure : A systematic review and meta-analysis. JAMA. 2020 ; 324 (1) : 57-67.
PubMed
2) 日本Covid-19対策ECMO-net. COVID-19関連重症者の人工呼吸管理. v1.4. 2020/03/10 https://www.jsicm.org/news/upload/COVID-19-ECMOnetreport_20200310.pdf [2021.6.18 アクセス時]
 
3) Demoule A. et al. High-flow nasal cannula in critically III patients with severe COVID-19. Am J Respir Crit Care Med. 2020 ; 202 (7) : 1039-42.
PubMed
4) Patel M, et al. Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-tosevere hypoxaemic respiratory failure. BMJ Open Respir Res. 2020 ; 7 (1) : e000650.
PubMed
5) Takazono T, et al. Effects of surgical masks on droplet dispersion under various oxygen delivery modalities. Crit Care. 2021 ; 25 (1) : 89.
PubMed
P.179 掲載の参考文献
1) Z Wu, et al. Time Course of a Second Outbreak of COVID-19 in Beijing, China, June-July 2020. JAMA. 2020 ; 324 (14) : 1458-9.
 
2) 一般社団法人日本集中治療医学会/一般社団法人日本呼吸療法医学会ARDS診療ガイドライン作成委員会. ARDS診療ガイドライン 2016. 日本集中治療医学会雑誌. 2027 ; 24 (1) : 57-63.
 
P.183 掲載の参考文献
1) Cook TM, et al. Consensus guidelines for managing the airway in patients with COVID-19 : Guidelines from the Difficult Airway Society, the Association of Anaesthetists the Intensive Care Society, the Faculty of Intensive Care Medicine and the Royal College of Anaesthetists. Anaesthesia. 2020 ; 75 (6) : 785-99.
 
2) Wax RS, Christian MD. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anaesth. 2020 ; 67 (5) : 568-76.
PubMed
3) Zuo MZ, et al. Expert Recommendations for Tracheal Intubation in Critically ill Patients with Noval Coronavirus Disease 2019. Chin Med Sci J. 2020 ; 35 (2) : 105-9.
PubMed
P.186 掲載の参考文献
1) 日本集中治療医学会, 日本呼吸療法医学会, 日本クリティカルケア看護学会. 3学会合同人工呼吸器離脱ワーキング. 人工呼吸器離脱に関する3学会合同プロトコル. https://www.jsicm.org/pdf/kokyuki_ridatsu1503b.pdf [最終アクセス 2021.6.18]
 
P.191 掲載の参考文献
1) McGrath BA et al. Tracheostomy in the COVID-19 era : global and multidisciplinary guidance. Lancet Respir Med. 2020 ; 8 (7) : 717-25.
PubMed
2) Trouillet JL et al. Tracheotomy in the intensive care unit : guidelines from a French expert panel. Ann Intensive Care. 2018 ; 8 (1) : 37.
 
3) Staibano P et al. Association of tracheostomy with outcomes in patients with COVID-19 and SARS-CoV-2 transmission among health care professionals : A systematic review and metaanalysis. JAMA Otolaryngol Head Neck Sur. 20211 ; 147 (7) : 646-55.
 
P.193 掲載の参考文献
1) Guerin C, et al. Mechanisms of the effects of prone positioning in acute respiratory distress syndrome. Intensive Care Med. 2014 ; 40 (11) : 1634-42.
PubMed
2) Alhazzani W, et al. Surviving Sepsis Campaign : guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020 ; 46 (5) : 854-87.
PubMed
3) Guerin C, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013 ; 368 (23) : 2159-68.
PubMed
P.194 掲載の参考文献
1) Badulak J, et al. Ex tracorporeal Membrane Ox ygenation for COV ID -19 : Updated 2021 Guidelines from the Extracorporeal Life Support Organization. ASAIO J. 2021 ; 67 (5) : 485-95.
 
2) Alhazzani W, et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU : First Update. Crit Care Med. 2021 ; 49 (3) : e219-e234.
PubMed
3) 厚生労働科学研究費補助金新興・再興感染症及び予防接種政策推進研究事業「新興・再興感染症のリスク評価と危機管理機能の実装のための研究」分担研究班. 日本COVID-19対策ECMOnet : COVID-19急性呼吸不全への人工呼吸管理とECMO管理 : 基本的考え方. 日本集中治療医学会雑誌. 2020 ; 27 : 447-52.
 
P.197 掲載の参考文献
1) Interim Guidance for Basic and Advanced Life Support in Adults, Children, and Neonates With Suspected or Confirmed COVID-19 : April 9, 2020, American Heart Association. Circulation. 2020 ; 141 : e933-43.
 
2) The Australian and New Zealand Intensive Care Society (ANZICS) COVID-19 Guidelines Version 3, October 20, 2020. https://www.anzics.com.au/wp-content/uploads/2020/10/ANZICS-COVID-19-Guidelines_V3.pdf [最終アクセス 2021.7.30]
 
3) Nolan JP, et al ; European Resuscitation Council COVID-Guideline Writing Groups. European Resuscitation Council COVID-19 guidelines executive summary. Resuscitation. 2020 ; 153 : 45-55
 
P.205 掲載の参考文献
1) Birkmeyer JD, et al. The impact of the COVID-19 pandemic on hospital admissions in the United States. Health Aff (Millwood). 2020 ; 39 (11) : 2010-17.
PubMed
2) 種田憲一郎. なぜチームトレーニングが必要か : チームSTEPPSの開発と普及. Medical forum CHUGAI. 2012 ; 16 (1) : 2-13.
 
3) Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 ; 323 (13) : 1239-42.
 
4) Berlin DA, et al. Severe Covid-19. N Engl J Med. 2020 ; 383 (25) : 2451-60.
PubMed
5) Luyt C, et al. Ventilator-associated pneumonia in patients with SARS- CoV-2-associated acute respiratory distress syndrome requiring ECMO : a retrospective cohort study. Ann Intensive Care. 2020 ; 10 (1) : 158.
PubMed
6) McWilliams D, et al. Rehabilitation levels in patients with COVID-19 admitted to intensive care requiring invasive ventilation. An Observational Study. Ann Am Thorac Soc. 2021 ; 18 (1) : 122-9.
PubMed
7) Eggmann S, et al. Early Physical Therapist Interventions for Patients With COVID-19 in the Acute Care Hospital : A Case Report Series. Phys Ther. 2021 ; 101 (1) : pzaa194.
 
P.208 掲載の参考文献
1) 日本嚥下医学会. 新型コロナウイルス感染症流行期における嚥下障害診療指針. 2020. https://www.ssdj.jp/new/detail/?masterid=113 [最終アクセス 2021.7.1]
 
P.213 掲載の参考文献
1) Wiersinga WJ, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19) ; A Review. JAMA. 2020 ; 324 (8) : 782-73.
PubMed
2) 新型コロナウイルス感染症 (COVID-19) 診療の手引き. 第5版. 2021 : https://www.mhlw.go.jp/content/000785119.pdf [最終アクセス 2021.6.20]
 
3) European Society of Medical oncology (ESMO). Introduction to the ESMO COVID-19 Palliative care pathways. https://www.esmo.org/covid-19-and-cancer/covid-19-resource-centre/covid-19-palliative-care-pathways [最終アクセス 2021.6.20]
 
4) 日本緩和医療学会. COVID-19関連特別ワーキンググループ特設ホームページ. 日本緩和医療学会COVID-19患者の咳嗽への対応に関する手引き. https://www.jspmcovid19.com/?p=252 [最終アクセス 2021.06.20]
 
5) 日本緩和医療学会. COVID-19関連特別ワーキンググループ特設ホームページ. 日本緩和医療学会COVID-19患者の呼吸困難への対応に関する手引き (在宅版). https://www.jspm-covid19.com/?p=238 [最終アクセス 2021.06.20]
 
6) 日本緩和医療学会. COVID-19関連特別ワーキンググループ特設ホームページ. 日本緩和医療学会COVID-19患者の呼吸困難への対応に関する手引き (病院版). https://www.jspm-covid19.com/?p=169 [最終アクセス 2021.06.20]
 
7) 山口崇. COVID-19に伴う呼吸困難・咳嗽への対応. 緩和ケア. 2020 ; 30 (4) : 258-64.
 
8) 廣橋猛. : COVID-19と緩和ケア : 院内感染の現場から. 緩和ケア. 2020 ; 30 (4) : 252-7.
 
9) 日本呼吸器学会・日本呼吸ケア・リハビリテーション学会合同 非がん性呼吸器疾患緩和ケア指針2021作成委員会編. 非がん性呼吸器疾患緩和ケア指針 2021. 東京, メディカルレビュー社, 2021. http://fa.jrs.or.jp/guidelines/np2021.pdf [最終アクセス 2021.6.21]
 
10) 日本緩和医療学会緩和医療ガイドライン委員会編. がん患者の呼吸器症状の緩和に関するガイドライン 2016. 東京, 金原出版, 2016.
 
P.226 掲載の参考文献
1) 厚生労働省. チーム医療の推進について (チーム医療の推進に関する検討会報告書). 2010年3月19日. https://www.mhlw.go.jp/shingi/2010/03/dl/s0319-9a.pdf [最終アクセス 2021.7.16]
 
2) 出原弥和, 篠田かおる. 多職種連携退院支援カンファレンスにおいて看護師が果たしている役割. 太成学院大学紀要. 2021 : 23 (40) ; 1-6.
 
3) 厚生労働省. 地域包括ケアシステム. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/hukushi_kaigo/kaigo_koureisha/chiiki-houkatsu/ [最終アクセス 2021.7.16]
 
4) 日本集中治療医学会. 新型コロナウイルス感染症 (COVID-19 関連情報). https://www.jsicm.org/covid-19.html [最終アクセス 2021.6.29]
 
P.237 掲載の参考文献
1) 日本クリティカルケア看護学会. 救急・集中ケアにおける終末期看護プラクティスガイド. 東京, 医学書院, 2020.
 
2) 日本クリティカルケア看護学会終末期ケア委員会, 日本救急看護学会終末期ケア委員会. 救急・集中ケアにおける終末期看護プラクティスガイド. 2019. http://jaen.umin.ac.jp/pdf/EOL_guide1.pdf [最終アクセス 2021.6.10]
 
3) Mercadante S, et al. Palliative Care in the Time of COVID-19. J Pain Symptom Manage. 2020 ; 60 (2) : e79-e80.
PubMed
4) 日本クリティカルケア看護学会, 日本集中治療学会. COVID-19重症患者看護実践ガイド ver.3.0. 2021. https://www.jaccn.jp/guide/pdf/COVID-19_guide1.Ver3.0.pdf [最終アクセス 2021.6.10]
 
5) Australian and New Zealand Intensive Care Society. ANZICS COVID-19 Guidelines version 3. Melbourne, ANZICS, 2020. https://www.anzics.com.au/wp-content/uploads/2020/10/ANZICSCOVID-19-Guidelines_V3.pdf [最終アクセス 2021.6.10]
 
6) Bloomer MJ, et al. Australian College of Critical Care Nurses and Australasian College for Infection Prevention and Control position statement on facilitating next-of-kin presence for patients dying from coronavirus disease 2019 (COVID-19) in the intensive care unit. Aust Crit Care. 2021 ; 34 (2) : 132-4.
PubMed
P.245 掲載の参考文献
1) 国立がん研究センター東病院. 惨事ストレス (臨界事態ストレス) における支援者のストレス対策. 2020年3月12日版. https://www.ncc.go.jp/jp/epoc/division/psycho_oncology/kashiwa/020/v1_1.pdf [最終アクセス 2021.7.16]
 
P.251 掲載の参考文献
1) Lai J, et al. Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA Netw Open. 2020 ; 3 (3) : e203976.
PubMed
2) de Pablo GS, et al. Impact of coronavirus syndromes on physical and mental health of health care workers : Systematic review and metaanalysis. J Affect Disord. 2020 ; 275 : 48-57.
 
3) 重村淳ほか. COVID-19 (新型コロナウイルス感染症) が及ぼす心理社会的影響の理解に向けて, トラウマティック・ストレス. 2020 ; 18 (1) : 1-9.
Medical*Online
4) 国立がん研究センター東病院. 惨事ストレス (臨界事態ストレス) における支援者のストレス対策. 2020年3月12日版. https://www.ncc.go.jp/jp/epoc/division/psycho_oncology/kashiwa/020/v1_1.pdf [最終アクセス 2021.7.16]
 
5) Perrin MA, et al. Differences in PTSD prevalence and associated risk factors among World Trade Center disaster rescue and recovery workers. Am J Psychiatry. 2007 ; 164 (9) : 1385-94.
PubMed
6) 日本赤十字社. 新型コロナウイルス感染症 (COVID-19) に対応する職員のためのサポートガイド. 2020年3月25日 初版第2刷.
 
7) Substance Abuse and Mental Health Services Administration (SAMHSA). Disaster Responder Stress Management. https://www.samhsa.gov/dtac/dbhis-collections/disaster-response-template-toolkit/disaster-responder-stressmanagement [最終アクセス 2021.7.8]
 
8) 重村淳監修, 小林佑衣翻訳. コロナウイルスやその他の感染症アウトブレイク中における医療従事者の健康維持. 2020年2月25日 (Center for the Study of Traumatic Stress, Department of Psychiatry, Uniformed Services University. Sustaining the Well- Being of Healthcare Personnel during Coronavirus and other Infectious Disease Outbreaks.) https://www.jstss.org/_files/00081191/file6.pdf [最終アクセス 2021.3.31]
 
9) 大竹直子. 自己表現ワークシート 2. 東京, 図書文化社, 2008.
 
10) 厚生労働省, 独立行政法人労働者健康安全機構. 職場における心の健康づくり : 労働者の心の健康の保持増進のための指針. 2020. https://www.mhlw.go.jp/content/000560416.pdf [最終アクセス 2021.8.25]
 

書評

最近チェックした商品履歴

Loading...